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ABSTRACT 
Cigarette smoking is one of the foremost causes of chronic obstructive pulmonary diseases such as 
emphysema and chronic bronchitis, and although it is the most preventable causes of death, it accounts 
for approximately 6 million deaths worldwide each year. Cigarette smoking during pregnancy and 
lactation remains one of the primary modifiable risk factors for undesirable fetal, obstetrical, and 
developmental outcomes. Consequently, the offspring of the smoking mother is exposed to nicotine 
via the blood and the milk of the mother. As a result, nicotine interacts with the developing offspring 
and therefore interferes with normal fetal lung development. Maternal smoking during gestation and 
lactation has been associated with both short and long term health risks ranging from intrauterine 
growth restriction to physiological abnormalities. Maternal smoking has also been strongly linked to 
an increased risk for pulmonary diseases and respiratory morbidity in the offspring of the smoking 
mother. The main objectives of this study were to determine the effects of maternal nicotine exposure 
during gestation and lactation on the alveolar wall composition during lung development in the 
offspring; if maternal nicotine exposure during gestation and lactation  induces premature cellular 
senescence in the lungs of the offspring; to clarify the role of pulmonary fibroblasts in premature 
senescence; and to establish whether tomato juice supplementation will prevent premature aging in the 
lungs of rats that were exposed to nicotine via the placenta and mother’s milk. From the data generated 
in this study it was evident that maternal nicotine exposure during gestation and lactation compromises 
the gas exchange function of the lungs of the F1 offspring. This was prevented by supplementing the 
mother’s diet with tomato juice which is then received by the offspring via the placenta and mother’s 
milk. This is conceivably achieved by maintaining the oxidant-anti-oxidant ratio of the mother and of 
the developing fetus and neonate, thereby averting premature senescence caused by nicotine exposure. 
Moreover, the present study also demonstrates that a decrease in fibroblast density is associated with 
emphysematous-like lesions in the lungs of the nicotine exposed F1 progeny. Since pulmonary 
fibroblasts are chief contributors to the extracellular matrix of the lungs, involved in alveolar 
multiplication and regeneration; premature aging or cessation of the metabolically active fibroblasts 
largely contributes to diminished lung structure and function. 
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CHAPTER ONE 
Literature Review 
 
1.1 Introduction 
Smoking is known to be the most preventable cause of death (Cnattingius, 2004) and accounts for 
approximately 6 million deaths worldwide each year (W.H.O., 2011). Villalbi and colleagues 
(2011) have shown that tobacco persists to be the second major cause of death in the world and 
continues to be the cause of superfluous deaths globally. Cigarette smoking during pregnancy and 
lactation remains one of the primary modifiable risk factors for undesirable fetal, obstetrical, and 
developmental outcomes (Andres and Day, 2000a). Furthermore, epidemiological studies show that 
maternal smoking during pregnancy and lactation is associated with adverse postnatal health, 
including, hypertension, obesity and type 2 diabetes (Blake et al., 2000). 
 
Tobacco smoke contains several potential cytotoxic agents, notably nicotine, which is a habit-
forming substance and thereby promotes damage to various systems including the respiratory, 
nervous, reproductive and cardiovascular systems (Fowles and Bates, 2000). Numerous studies 
have shown that a number of diseases brought on and/or aggravated by tobacco smoke are induced 
by nicotine (Maritz et al., 2011a). Several laboratory studies have shown that nicotine alters the 
structural development of the lungs (Maritz et al., 2011a, Sekhon et al., 2001), as well as its 
metabolism as the lungs age (Bruin et al., 2008b). Consequently this leads to a gradual deterioration 
of organ function with a concomitant increase in susceptibility to disease (Maritz and Windvogel, 
2003). 
 
1.2 Lung development 
Lung development necessitates the incorporation of numerous regulatory factors which facilitate 
cell proliferation, differentiation, migration and death. These developmental platforms, such as 
signalling molecules and transcriptional factors are most likely to be re-recruited during lung repair 
or recovery subsequent to injury (Deutsch and Pinar, 2002). In order to understand the mechanisms 
of lung disease, it is imperative to have a general comprehension of normal lung development and 
function. The lung is designed to afford a large internal surface where both inspired air and 
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capillary blood come into intimate contact with each other for efficient gaseous exchange (Schittny 
and Burri, 2008).  
 
1.2.1 Prenatal lung development 
In humans, lung development is initiated at 3-4 weeks of gestation in comparison to that of rats 
which is 11.5 days post-conception (Warburton et al., 2005, Schittny and Burri, 2008). Lung 
development can be divided into two periods, namely, the prenatal (in utero) period and the 
postnatal period. In humans, the prenatal period consists of the embryonic, pseudoglandular, 
canalicular and terminal sac or saccular phases. The postnatal period is comprised of the lung 
expansion, rapid alveolarisation (alveolar) and equilibrated lung growth phases (Maritz et al., 
2005). The timing of advancement from phase to phase may vary in other species and in some 
instances  alveolarisation may occur postnatally (Hall et al., 2002). 
  
 1.2.1.1 Embryonic 
The prenatal period is established by the embryonic stage from weeks 4-7 and day 13 of gestation 
in humans and the rat respectively (Pinkerton and Joad, 2000), where the respiratory diverticulum 
(lung bud) appears as an extension from the ventral wall of the foregut  known as the 
laryngotracheal groove  (Joshi and Kotecha, 2007, Sadler, 2009). Epithelial cells from the foregut 
endoderm invade the neighbouring mesenchyme to form the trachea (Joshi and Kotecha, 2007). The 
trachea then subdivides into the right and left bronchi and subsequently into the lobar and 
segmental bronchi. In humans the lobar and segmental bronchi emerge around the 5
th
 week (Jeffery, 
1998) and at this point, 18 major lobules are noticeable (Kotecha, 2000). Also, the two lungs are 
easily distinguishable by the 6
th
 week (Hall et al., 2002). In humans pulmonary veins and arteries 
develops as a single avascular bud from the 6
th
 aortic arch and persists to sprout  by vasculogenesis 
around the airway buds from weeks 4-16 (Hislop and Pierce, 2000). 
 
 1.2.1.2  Pseudoglandular 
This phase takes place from week 7-16 in humans and day 16 in the rat fetus (Pinkerton and Joad, 
2000). This stage is so named as the lungs take on a distinct glandular appearance (Pinkerton and 
Joad, 2000). Airways are lined by columnar epithelium and separated by a poorly differentiated 
mesenchyme, and more distal structures are lined by cuboidal epithelium (Pinkerton and Joad, 
 
 
 
 
3 
 
2000). The mesenchyme plays a key role in the development of the lung into a fully functional 
organ. Mesenchyme directs the growth and cytoarchitecture of a number of organs, including the 
lung in an organ specific manner (Windvogel, 2006b). In the lung the mesenchyme regulates 
growth and differentiation of the lung epithelium at the cellular-molecular level by means of 
various growth and differentiation factors that are hormonally regulated (Torday, 1992). During this 
phase cell proliferation is at its peak and large quantities of glycogen occur in respiratory epithelial 
cell types. This may also significantly modify gene expression and ultimately, lung development 
and growth (Pinkerton and Joad, 2000). 
 
 1.2.1.3 Canalicular 
The canalicular stage occurs from weeks 16-24 in the human fetus and days 19-20 in the rat 
(Pinkerton and Joad, 2000). This stage is marked by the proliferation of the mesenchyme and the 
development of a rich blood supply within in the mesenchyme (El-Hashash et al., 2011), as well as 
the flattening of the respiratory epithelium that lines the airways (Thurlbeck, 1975). The rapid 
formation of capillaries can be observed which protrude into the epithelium and occasional areas of 
a thin blood-air barrier, similar to that of an adult, appear. Type I and II cell differentiation occurs 
and the production of surfactant in type II cells commences (Sadler, 2009). 
 
 1.2.1.4  Saccular 
The terminal or saccular stage of lung development in humans is marked from week 24 to near term 
and in the rat from day 21 (Pinkerton and Joad, 2000). The most peripheral airways form enlarged 
airspaces termed saccules which widen and lengthen by the addition of new generations. The 
impending gas regions increase significantly. As a result of cell differentiation, type I and II cells 
can clearly be distinguished (Haworth and Hislop, 2003). Lamellar bodies are characteristic of type 
II cells and are  produced by the cells at about prenatal week twenty four in humans, and surfactant 
can be detected in the amniotic fluid four to five weeks later (Haworth and Hislop, 2003). A close 
correlation exists between the appearance of lamellar bodies in the type II cells and the presence of 
surfactant in the amniotic fluid. The loss of glycogen from the type II cells is associated with the 
formation of surfactant (Ridsdale and Post, 2004). 
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1.2.2 Postnatal lung development: 
 1.2.2.1 Lung expansion 
In humans and rats this stage occurs just after birth (Burri, 1985) and the lung volume increases 
almost exclusively from an enlargement of the existing airspaces (Maritz and Dennis, 1998). Lung 
volume escalates proportionally to body weight during the first 10 days and thereafter is allied to 
lung volume (Burri et al., 1974).  
 
 1.2.2.2  Rapid alveolarisation 
Depending on species this stage may be initiated before birth and continued postnatally. In altricial 
species such as rats (Burri, 1974, Burri et al., 1974), mice (Amy et al., 1977) and humans (Zeltner 
and Burri, 1987, Zeltner et al., 1987), alveolarisation is a relatively postnatal event. However, in 
precocial animals like in sheep (Alcorn et al., 1981) and guinea pigs (Sosenko and Frank, 1987) 
alveolar formation is initiated well before birth, and at term their lungs seem virtually developed. 
Burri et al. (1974) suggested that the establishment of secondary septa necessitates a double-layered 
capillary network in the pre-existing septum from which the novel septum is elevated and each 
section has an “exclusive” capillary bed. The preceding structural arrangement permits an upfolding 
of the capillary network of one septal side, whilst ensuring blood supply of the other side. 
Additionally, subsequent to maturation of the alveolar microvasculature from a double-layered to a 
single-layered capillary complex, the formation of novel alveoli was no longer identified in 
developmental studies achieved by morphological examination of lung sections. Hence, it was 
assumed that there is a cessation in growth of new alveolar septa or new alveoli following the 
completion of microvascular maturation. More recent findings using more modern technology and 
techniques such as synchrotron radiation-based X-ray tomographic microscopy (Schittny et al., 
2008), and quantitative methods  (Ochs et al., 2004, Hyde et al., 2007), showed that alveoli or the 
estimation of the free septal edge (Schittny et al., 2008) are formed until young adulthood. This can 
be seen in Rhesus monkeys, rats, mice and humans (Hyde et al., 2007, Mund et al., 2008, Schittny 
et al., 2008, Butler et al., 2012, Narayanan et al., 2012).  
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Figure 1.2.2.2: The Biphasic Formation of New Alveoli during Postnatal Lung Development. Adapted 
fromTschanz et al. (2014). 
Tschanz and colleagues (2014) recently demonstrated that alveolar formation of novel alveoli is 
biphasic throughout postnatal lung development. In rats, the first phase of alveolar formation (days 
4-10) is known as “bulk alveolarisation”, while the second phase (days 21-60+) is termed 
“continued alveolarisation”. Bulk alveoli formation was observed between days 4 and 21 with a 
17.4 times increase from 0.8 to 14.3 million alveoli, while between days 21 and 60, termed 
continued alveolarisation, a 1.3 times increase to 19.3 million alveoli was observed. At day 4 
during the phase of bulk alveolarisation in rats the mean volume of alveoli decreases from 
~593,000 µm
3 
to 141,000 µm3 at postnatal day 21. However, it again increases to 298,000 µm3 at 
day 60 after birth (Tschanz et al., 2014). Additionally, it was concluded that “bulk alveolarisation” 
correlates with process of classical alveolarisation (alveolarisation prior to microvascular 
maturation completion) and that “continued alveolarisation” follows three suggested mechanisms of 
late alveolarisation (alveolarisation subsequent to microvascular maturation) (Burri, 2006, Schittny 
et al., 2008).  
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The first proposed mechanism corresponds to classical ongoing alveolarisation whereby the 
development of novel alveolar septa occurs at sites where the alveolar microvasculature had not 
entirely matured, and thus the obligatory double-layered capillary network persists. This is about 5-
10% of the capillary network (Roth‐Kleiner et al., 2005). Secondly, it occurs at sites of matured 
single-layered capillary networks by a central and interim reduplication of the capillary bed that can 
establish conditions for septal upfolding. Aforesaid reduplication was undeniably found in vascular 
casts at sites where new interalveolar septa began to surface (Schittny et al., 2008).  
 
The second mechanism can function ubiquitously in the lung parenchyma. Although considered as 
an augmented mechanism of late alveolarisation, a rat model done by Roth-Kleiner and colleagues 
(2005) and Schittny and co-workers (2008) respectively, observed that alveolarisation was 
experimentally dampened by several glucocorticoid treatments. Following treatment, undeveloped 
septa with dual capillary layers resurfaced and a considerable resurgence of alveolarisation was 
observed. Since alveolar walls possess an exclusive capillary bed, the third mode of alveolarisation 
occurs at the parenchymal border where alveoli lay adjacent to non-parenchymal structures namely 
bronchi, vessels, and pleural tissue. It has been suggested that an upfolding of novel septa may well 
occur throughout life at these sites (Burri, 2006). The former denotes the only type of 
alveolarisation that does not necessitate a double-layered capillary system since gas exchange only 
takes place on one side unlike that of the mature alveolar septa which require opposing sides of the 
capillary network. Furthermore, it is proposed that the three mechanisms of late alveolarisation 
eventuate during the course of postnatal lung development subsequent to most alveolar septal 
maturation.  
 
As reported by Tschanz and co-workers (2014), all modes fulfil the prerequisite of a “private” 
capillary bed per septal edge, where one side strives to fold up and form a new interalveolar 
septum. They concluded that continued alveolarisation, following the completion of microvascular 
maturation, may possibly serve as an explanation for the lungs potential to both structurally and 
functionally adapt to environmental fluctuations such as hypoxia and to recuperate subsequent to  
resection of lung tissue (Burri and Weibel, 1971, Ravikumar et al., 2009). Functional recovery of 
the lung was observed after pneumonectomy and other experimental/clinical studies for humans, 
mice, rats and dogs (Burri and Sehovic, 1979, Wandel et al., 1983, Nakajima et al., 1998, Takeda et 
al., 1999, Brown et al., 2001, Hsia, 2004, Fehrenbach et al., 2008, Butler et al., 2012). This suggests 
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that the lung is not only proficient in partially re-establishing the diffusion surface area by 
expansion of airspaces but also capable of forming new airspaces. Moreover, the biphasic pattern is 
more apparent for the growth in alveolar number than for the formation of new alveolar septa 
(Tschanz et al., 2014). 
 
 1.2.2.3 Equilibrated lung growth 
This phase is also known as microvascular maturation. In the human it lasts from birth to the age of 
3 years whereas in the rat it lasts from postnatal days 14 to 21 (Schittny and Burri, 2008). This 
stage is associated with final maturation of the lung by increasing the surface area through the 
formation of more alveoli as well as expansion of the existing alveoli (Schittny and Burri, 2008). At 
this stage the capillaries are intimately associated with the blood-air barrier which is vital for 
optimal gaseous exchange in the organism. 
 
1.2.3 Factors affecting lung development 
An intricate synergistic role exists between various factors that affect lung development. Earlier 
studies have documented that various environmental substances (e.g. endocrine disruptors), 
physiological stress (e.g. caloric restriction) and therapeutic treatments (e.g. diethylstilbestrol, DES) 
during embryogenesis and/or early postnatal lung development may encourage lung disease 
(Skinner, 2009). Other interrelated factors include developmental, genetic and mechanical factors. 
Examples of these factors include both fetal and maternal nutrition, endocrine factors, normal fetal 
lung fluid production, adequate intrathoracic and extrathoracic space, adequate amniotic fluid 
volume, positive transpulmonary pressure to conventional postnatal acclimatisation (Mesas-Burgos 
et al., 2009). The fetal lung is highly prone to changes in the environment during rapid cell 
proliferation. Certain windows of opportunity exist as a result of the vastly influential lung and may 
have adverse or beneficial effects. These effects are dependent on the timing, duration, severity and 
type of effect imparted on the fetal lung during development (Fowden et al., 2006). 
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1.3 Alveolar wall cells 
1.3.1 Alveolar Epithelial Type I and Type II Cells 
Pulmonary alveolar walls are composed of Type I and Type II epithelial cells, endothelial cells and 
fibroblasts. Two cell types occupy the alveolar epithelium in normal adult lungs, namely the 
alveolar epithelial type I (ATI) cells, and the alveolar epithelial type II (ATII) cells. The ATI cells 
cover 95% of the internal surface area (ISA) of the lung. ATI cells are branched cells with 
compound apical surfaces that continue into adjacent alveoli (Weibel, 1984). Additionally, ATI 
cells are characterised by very large apical surfaces in contrast to most cells (i.e. 5000µm2 for 
human ATI cells), and are very thin cells (i.e. 0.2 µm in depth) (Weibel, 1984, Pinkerton et al., 
1992). Furthermore, the gas exchange barriers of the lungs are occupied by the ATI cells along with 
endothelial cells joined by a fused basement membrane. ATI cells are also imperative in the 
regulation of alveolar fluid balance and surfactant secretion by ATII cells in response to stretch 
(Stevens et al., 2000, Boers et al., 1999, Kuhn et al., 1974). The ATII cells cover the remaining 2-
5% of the lungs surface area (SA). ATII cells are cuboidal in shape found between ATI cells and 
enclose characteristic lamellar bodies and apical microvilli (Weibel, 1984). Moreover, the ATII 
cells possess many known functions which include the production, secretion and reuptake of 
pulmonary surfactant (Niden, 1967), regulation of alveolar fluid in normal lungs and during the 
resolution of pulmonary oedema (Rehan et al., 2007b), synthesis and secretion of 
immunomodulatory  proteins essential for host defences e.g. surfactant proteins A and D (Roman, 
2012, Virender et al.). 
 
1.3.2 Response of the epithelium to injury 
Damaged ATI cells are replaced by ATII cells (Evans et al., 1975, Adamson and Bowden, 1974, 
Adamson and Bowden, 1975, Geiser, 2003, Uhal, 1997) (reviewed in (Uhal, 1997)). Studies done 
by Evans and colleagues in particular, provide the groundwork of existing knowledge regarding the 
response of the alveolar epithelium to injury. They studied ultrastructural changes to the alveolar 
epithelium following the exposure to the oxidant nitrogen dioxide (NO2) for 48 h. In alveoli 
neighbouring to terminal bronchioles, the ATI cells were maximally damaged following 8-12 hr 
exposure (Evans et al., 1972). Subsequent to 48 h exposure, the denuded basement membranes 
were repopulated by cuboidal epithelial cells several of which were ATII cells (Evans et al., 1975). 
Proliferating cells were labelled with tritiated thymidine, which is integrated into newly synthesized 
DNA during the S phase of the cell cycle. Following 48 h exposure to NO2, majority of the labelled 
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cells were ATII cells; however, after an additional 48 h recovery, the number of labelled ATII cells 
had diminished, though the number of ATI cells had increased. Additionally, over the 48 h 
recuperation period, a temporary upsurge was seen in label associated with alveolar epithelial cells 
(AEC) having both ATI and ATII cell characteristics (i.e. ATII-like cells but extended across the 
basement membrane or ATI-like cells possessing occasional microvilli and lamellar bodies) (Evans 
et al., 1975). These studies display three vital aspects of alveolar epithelial injury and repair: 1) the 
loss of AT1 cells can herald ATII cell proliferation, 2) alveolar epithelial repair involves the 
transformation of ATII cells (or a subset thereof) into novel ATI cells and 3) the transformation of 
ATII cells into ATI cells does so via intermediate cell types. 
 
More recent studies have demonstrated that subpopulations of ATII cells may be present with 
dissimilar proliferative capabilities subsequent to injury (Reddy et al., 2004). However, the 
probability for these supposed ATII cell subpopulations to transdifferentiate into ATI cells is 
unknown. Injured ATI cells may also be reinstated by bone marrow and noncilliated bronchiolar 
epithelial progenitor cells (Daly et al., 1998, Kotton et al., 2001). For a long time it was speculated 
that ATI cells were terminally differentiated. However, studies intended to investigate the role of a 
mechanical load in fetal lung development propose that ATI cells have the potential to 
transdifferentiate into ATII cells (Flecknoe et al., 2002). It is unknown whether ATI cells are 
capable of replacing ATII cells in injured adult lungs.  
 
1.3.3 Fibroblasts 
Fibroblasts are spindle shaped cells found in majority of tissues and organs of the body associated 
with extracellular matrix (ECM) molecules. Distinctive features include the expression of vimentin 
in the absence of desmin and α-smooth muscle actin (SMA) (McAnulty, 2007).  Once activated, 
these cells display and an abundant endoplasmic reticulum (ER) and a prominent Golgi allied with 
the synthesis and secretion of ECM molecules including fibronectin, collagens, and proteoglycans, 
together with proteases capable of degrading the ECM. Both cytoskeletal proteins and cell surface 
integrins in association with the ECM facilitate cell motility and the initiation of contractile forces 
crucial in tissue homeostasis and wound healing (McAnulty, 2007). 
 
Fibroblasts are embryologically of mesenchymal descent with a range of phenotypic entities 
varying from the non-contractile fibroblast to the contractile myofibroblast along with a number of 
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intermediate phenotypes having been described (Eyden, 2005) such as protomyofibroblast 
(DesmouliÃ¨re et al., 2003). One of the major functions of fibroblasts is the production and 
homeostatic maintenance of the ECM of the organ or tissue which they inhabit. They are 
metabolically highly active cells, capable of synthesizing and secreting majority of the ECM 
components, including collagens, proteoglycans, fibronectin, tenascin and laminin. Fibroblasts 
constantly synthesize ECM proteins and it has been predicted that each cell is able to synthesize 
approximately 3.5 million procollagen molecules/day (McAnulty et al., 1991). However, the 
quantity they secrete is regulated by lysosomal enzymes, for instance cathepsins B, D and L; amid 
10% and 90% of all procollagen molecules being degraded intracellularly prior to secretion, 
depending on tissue and age. Control of this process seems to impart a mechanism for a hurried 
adaptation of the amount of collagen secreted subsequent to injury (McAnulty and Laurent, 1995). 
Additionally, fibroblasts produce matrix metalloproteinases (MMP) along with their inhibitors, that 
is, tissue inhibitors of metalloproteinase (TIMP), which regulate extracellular degradation of the 
ECM. Fibroblast ECM metabolism is modulated by complex mechanisms including cell-cell and 
cell-matrix interactions, along with a host of stimulatory and inhibitory mediators, which may be 
found in their resident environment (McAnulty and Laurent, 2002). Mediators involved include 
those which are; a) derived from other resident cells in the local environment, b) fibroblasts 
themselves, and c) mediators resulting from the circulation or infiltrating inflammatory cells. 
 
Apart from its function in producing the components of the ECM, fibroblasts are also in direct 
contact with alveolar epithelial cells and air-blood barrier endothelial cells. The fibroblasts appear 
to form an interconnected reticular network that extends from the distal alveoli to the more 
proximal conducting airways (Evans et al., 1999). This implies that the fibroblasts play an 
important role in maintaining lung structural and functional integrity. In addition, if these cells are 
compromised it will adversely affect lung structural integrity and function. 
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1.3.3.1 Fibroblasts in tissue injury 
Subsequent to tissue injury both fibroblasts and myofibroblasts play a fundamental role in wound 
healing and tissue repair (reviewed by (DesmouliÃ¨re et al., 2003). The general processes following 
injury involves clot formation and platelet aggregation, discharging mediators to attract 
inflammatory cells to the site of the wound which will produce additional mediators implicated in 
the recruitment of fibroblastic cells stemming from a number of sources as explained above 
(McAnulty, 2007). In this early phase of injury, the present fibroblastic cells are exceedingly active, 
synthetically exchanging impermanent matrix with a more mature ECM including collagens and 
fibronectin under the regulation of inflammatory mediators, regenerating injured epithelial cells, 
and fibroblasts themselves. With the progression of granulation tissue deposition, the fibroblasts 
acquire the characteristics of myofibroblasts, along with the appearance of α-smooth muscle 
holding stress fibers (McAnulty, 2007). The manifestation of these myofibroblasts correlates with 
the contraction and closure of the wound through central adhesions between the ECM and 
myofibroblasts. In the concluding phases of resolution and remodelling, the assembly of MMPs and 
TIMPs by cells as well as fibroblasts becomes altered from a balance favouring ECM accretion to a 
matrix reducing environment while myofibroblasts are eliminated by apoptosis. Residual 
fibroblasts display a more dormant, noncontractile phenotype which may possibly have regressed 
from a myofibroblasts phenotype or stemmed from a source of cells uninvolved in the 
differentiation into myofibroblasts. Dysregulation of the injury-repair response may well advance 
into unsuccessful or over exuberant and pathological wound healing (McAnulty, 2007). 
 
Several diseases concomitant with diminished or excess accretion of ECM are possibly linked to 
dysregulation of the injury-repair response along with fibroblast function. The term “injury” is far 
reaching in this context and encompasses infectious, environmental, traumatic/mechanical, 
cancerous, drug induced and autoimmune insults. Therefore, associated pathologies involving 
fibroblasts, in their various phenotypic forms, play a crucial role in tissue maintenance, which in 
turn may affect almost all tissues and organs of the body (McAnulty, 2007). This is further 
supported by the suggestion that virtually half of all deaths are as a result of fibrosing conditions. 
Diseases associated with the imbalance ECM deposition or degradation, or contraction of tissues 
are likely to give rise to distorted tissue architecture, diminished function, and in most cases, 
especially with the involvement of vital organs, substantial morbidity and mortality. Dysregulation 
of a number of phases of the injury-repair response, along with an inadequate inflammatory 
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response, chronic or recurring injury, altered phenotypic forms, an imbalance of ECM metabolism 
and deposition or persistence of myofibroblasts, participate in anomalous tissue repair (McAnulty, 
2007). Currently, no treatments exist which specifically target fibroblast-associated pathologies. 
However, present therapeutic strategies are predominantly revolving around the use of anti-
inflammatory corticosteroids, immunosuppressants and treatment of specific tissue or disease 
symptoms. Furthermore, at most the aforementioned have restricted therapeutic effects (McAnulty, 
2007). 
 
1.3.3.2 Role of pulmonary fibroblasts 
Lung fibroblasts are the primary cell type responsible for synthesis and secretion of the chief 
alveolar extracellular matrix components, collagen, proteoglycan, and elastin, as well as 
maintenance of the alveolar ECM, which is the crucial foundation over which other cells 
differentiate and proliferate. Elastin in particular is a fundamental element of the alveolar 
extracellular matrix since it provides the lung with its key mechanical characteristic, elasticity 
(Plantier et al., 2007). Elasticity is required for ventilation and elastin synthesis is a vital feat for 
both alveolar growth and regeneration. Apart from its invaluable role as ECM contributor, in both 
fetal (Warburton and Bellusci, 2004) and adult lungs, alveolar fibroblasts partake in compound 
cellular interactions that result in alveolar growth and multiplication (Plantier et al., 2007). 
 
Fibroblasts act together with both epithelial and endothelial cells via the discharge of soluble 
factors that act in a paracrine manner. Fibroblasts in particular, are the chief, if not the exclusive 
source of keratinocyte growth factor (KGF) in the distal lung and contributes considerably to the 
upsurge of lung hepatocyte growth factor (HGF) levels in response to alveolar damage (Stern et al., 
2000, Marchand-Adam et al., 2005, Cohen et al., 2006). It has been reported by Sirianni et al. 
(2003) that the role of fibroblasts in the control of cell-cell interactions in alveoli may not be 
restricted to the secretion of paracrine signal molecules as cytoplasmic expansions deriving from 
those cells arrive at the alveolar epithelial and endothelial cells by means of their respective 
basement membranes. Furthermore, fibroblasts play a key role in alveolar multiplication and 
regeneration and is believed that the fulfilment of such phenomenon necessitates metabolically 
active and proliferating fibroblasts (Plantier et al., 2007). 
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It is quite clear that the characteristics of all the cells are important for lung development and for 
the maintenance of lung structural integrity and also lung function. Any interference with these 
cells by, e.g., smoking or nicotine or any drug, may compromise lung development and lung 
structure and function. Development of the lung in utero and also after birth is a controlled process. 
Any interference with normal development during especially the phases of rapid cell proliferation 
in utero and early neonatal lung development may induce programming of the lungs to become 
more prone to diseases later in life. 
 
1.4 Pulmonary innate immunity 
The innate immune system is a non-specific defence mechanism which plays a central role in lung 
antimicrobial defences from birth. Innate immunity in the lung is comprised of lung leukocytes 
along with epithelial cells that line the alveolar surface and the conducting airways (Martin and 
Frevert, 2005). The significance of innate immunity is well demonstrated by the fact that 
pulmonary internal surface area which is about 70 m
2
, is
 
subjected to the inhaled atmospheric air. 
Given that many unknown substances occur in the inhaled air, from the first breath at birth, this 
necessitates an effective protection mechanism to avert infection and lung parenchymal damage 
(Derscheid and Ackermann, 2013). Additionally, the innate immune system also has influential 
interactions with other systems such as apoptosis and signalling pathways prompted by mechanical 
stretch (Martin and Frevert, 2005). Moreover, innate immunity also drives adaptive immunity 
which includes both cell-mediated and humoral immunity mechanisms. However, unlike  that of 
the adaptive immune system, the innate immune system is not highly specific to a specific 
pathogen. Therefore, the innate immune system is of particular importance in infants, especially 
preterm neonates, immunosuppressed individuals, and the elderly due to the fact that the adaptive 
immune system function is defective in each of these groups (Derscheid and Ackermann, 2013). 
 
1.4.1 Alveolar Macrophages (AM) 
Alveolar macrophages (AM) occur freely in the alveoli and constitute approximately 95% of 
airspace leukocytes, while only 1 to 4% is lymphocytes and around 1% is neutrophils. This is 
indicative that the alveolar macrophage is the most crucial phagocytic cell of pulmonary innate 
immunity. Alveolar macrophages play a crucial role in the protection of the lung. It does so by 
directly binding, phagocytose and kill pathogens. Alveolar macrophages derive from fetal 
monocytes that seed the lungs during late embryogenesis (Ginhoux, 2014). The first signs of AM 
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differentiation appeared around the saccular stage of lung development. Mature AM were 
undetectable before birth and only fully colonized the alveolar space by 3 d after birth. 
Development of AM is dependent on granulocyte-MF colony-stimulating factor (GM-CSF) and M-
CSF for their development. It has been found that around the perinatal period, high expression of 
GM-CSF mRNA in epithelial cells and protein in BAL fluid is high, but decreased rapidly after 
birth (Guilliams et al., 2013). From this it appears that the epithelial cells plays and important role 
in creating an environment for the development and differentiation of the AMs. 
 
                                   
                
 
 
 
 
    
                
Although there are studies that demonstrate that the phagocytic capacity of the AM of neonates is 
not as well developed as in the adult lung, other studies suggest that there is no difference in the 
capacity of the AM between neonates and adult lung. In addition to phagocytosis AM also secrete a 
large number of mediators, some of which act directly with pathogens while others, such as 
chemokines exert their effects indirectly by recruiting other components of the immune system. 
This latter process is relatively inefficient in the neonate (Martin et al., 1995). 
 
In a study by Wongtrakool et al. (2012) it was demonstrated that in utero nicotine exposure induces 
a TH2 milieu in the neonatal lung resulting in a skewed distribution of the AM towards M2 
activation, thereby compromising AM function. As a consequence, phagocytosis becomes impaired 
and thus a decline in its ability to protect the lung against foreign inhaled substances rendering it 
more susceptible to disease. Whether this effect of nicotine is permanent is not known. It is known 
though that cigarette smoke also impairs clearance of bacteria from the lungs leading to 
inflammation and morbidity related to epithelial damage (Mehta et al., 2008). 
A B 
Figure 1.4.1: A) Alveolar macrophages occurring freely in the alveoli (Black arrow) and type II alveolar cell 
(Blue arrow). B) Scanning electron micrograph of an alveolar macrophage isolated from a bronchioalveolar 
lavage. 
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1.4.2 The role of alveolar Type I and Type II cells in innate immunity 
Although the alveolar macrophages and dendritic cells play a key role in pulmonary innate 
immunity, alveolar epithelial cells are also quite crucial. The alveolar type I and type II cells are 
morphologically very different and contribute significantly to protection of the lung. Termed 
“defenders of the alveolus”, alveolar type II (ATII) cells account for 3-5% of the internal surface 
area (ISA) of the lung. ATTII cells produce a vast number of cytokines and chemokines including 
interleukin-6 (IL-6), interleukin-1β (IL-1β), tumour necrosis factor-α (TNF-α), granulocyte-
macrophage colony stimulating factor (GM-CSF), macrophage inhibitory protein-1α (MIP-1α), 
monocyte chemoattractant protein 1 (MCP-1), and growth related oncogene-α (GRO-α) in response 
numerous forms of lung injury induced by inhaled viruses, bacteria or mechanical ventilation 
(Wong et al., 2012). Furthermore, the ATII cells produce surfactant which is not only important in 
alveolar stability, but also augments chemotaxis, and the engulfment of bacteria by the alveolar 
macrophages via phagocytosis (Tenner et al., 1989, Wright, 2004). 
 
Alveolar type I (ATI) cells covers approximately 95% of the ISA of the lung (Stone et al., 1992) 
and not only acts as a physical barrier to counteract inhaled particular, but is also involved in the 
active cellular response of the lungs to these inhaled particles. Contrary to earlier reports, it has 
been suggested that ATI cells actively participate in innate immunity. These cells express toll-like 
receptors such as Toll-like receptor 4 (TLR-4) and RAGE, however, they also produce pro-
inflammatory cytokines such as TNF-α, IL-6, and IL-1β in response to lipopolysaccharides (LPS). 
Studies suggest that the roles of ATI and ATII cells in inflammation is unalike and that these two 
cell types that line the enormous ISA of the lungs work simultaneously to safeguard the lungs 
against respiratory diseases. This is further supported by the observation that several of the 
inflammatory mediators are highly expressed in the ATI cells than in the ATII cells (Wong et al., 
2012). 
 
1.5 Cigarette smoking 
Cigarette  smoke contains more than 4700 chemical compounds which includes oxidants and free 
radicals (Rahman and MacNee, 1996). Approximately 60 of these were identified as both human 
and/or animal carcinogens (Fowles and Bates, 2000). The most highly recognized component of 
cigarette smoke is nicotine, a tertiary amine (Buccafusco, 2004), which is responsible for the 
habitual use of tobacco. It is one of the leading causes of disease and premature death in both 
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developed and developing countries (Moore et al., 2009). Cigarette smoke contains free radicals in 
both the gas and the tar phases and contains approximately 10
15 
radicals per puff (Rahman and 
MacNee, 1996). According to Rahman and MacNee (1996) oxidants found in cigarette smoke can 
cause direct damage to the lung matrix itself, particularly the collagen and elastin. It can also 
interfere with elastin repair and synthesis. This interference contributes to the degradation of elastin 
thus leading to the possible development of emphysema (Rahman and MacNee, 1996). 
 
1.5.1 Maternal exposure to tobacco smoke 
Environmental tobacco smoke (ETS) remains an important worldwide public issue and has been 
grouped by the Environmental Protection Agency (EPA) as a human lung class A carcinogen, along 
with asbestos and radon. Tobacco smoking during pregnancy remains widespread particularly in 
indigenous populations, and most likely promotes respiratory illnesses in the exposed offspring. It 
is now accepted that constituents of tobacco smoke, notably nicotine, can have a multitude of 
deleterious effects on the organs of the fetus and neonate , potentially with life-long consequences 
(Maritz and Harding, 2011a).  
 
While an increasing body of evidence exists which strongly link maternal tobacco smoking to fetal 
morbidity and mortality and obstetric disease, many pregnant females continue to smoke (Jimenez-
Ruiz et al., 2006).Maternal smoking during gestation and lactation has been associated with both 
short and long term health risks ranging from intrauterine growth restriction to physiological 
abnormalities (Brion et al., 2010). Low birth weight (LBW), sudden infant death syndrome (SIDS), 
perinatal complications, altered neurodevelopment, obstructive lung diseases, cancers and 
childhood infections (Hofhuis et al., 2003b) as well as an increased prevalence of lifestyle 
cardiovascular risk factors amongst offspring of  smoking parents (Horta et al., 2011). Studies show 
that maternal smoking increases the comparative risk of admission to a neonatal intensive care unit 
(NICU) by virtually 20%. As a result of maternal smoking, it further increased the length of stay 
whereas for non-NICU infants it seemed to decrease. Moreover, among mothers who smoke, 
smoking adds over $700 (± R 8054.08) in neonatal costs. These costs are decidedly avoidable given 
that the hostile effects of maternal nicotine exposure occur in the short-term and can be prevented 
by even the brief cessation of maternal smoking. These expense estimates can be utilised by local 
and state public health officials, managed care plans and others to assess alternative smoking 
cessation programs (Adams et al., 2002).  
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Maternal smoking has also been strongly linked to an increased risk for pulmonary diseases and 
respiratory morbidity in the offspring of the smoking mother (Horta et al., 2007, Kramer, 1987). In 
addition, epidemiological studies have shown a close relation between abnormal pulmonary 
function in infants and children and maternal exposure to cigarette smoke (Brion et al., 2008, Brion 
et al., 2010, Jaddoe et al., 2008).As a result of this, the developing fetus, or lactating infant whose 
mother smoked during pregnancy and/or lactation, are more likely to have decreased lung function 
and subsequently or additionally increased susceptibility to respiratory diseases later in life (Ruiz, 
2006).  Even though there is a substantial body of supporting evidence that states smoking during 
pregnancy is detrimental (Schwartz et al., 1972), an estimation of about 15%-20% of woman smoke 
throughout gestation (Andres and Day, 2000a, Bergmann et al., 2003). Previous studies have 
approximated that 5%-10% of fetal and neonatal deaths are as a result of maternal tobacco or 
nicotine exposure (Proskocil et al., 2005). 
 
1.5.2 Nicotine 
Nicotine, is a natural ingredient operating as a botanical insecticide in tobacco leaves, and is the 
principle alkaloid found in tobacco smoke. Nicotine underlies tobacco addiction, contributes to 
tobacco use patterns, and is used as a pharmacological aid for the cessation of smoking, otherwise 
known as nicotine replacement therapy (NRT) (Benowitz et al., 2009). It’s about 1.5% in weight of 
commercial cigarette tobacco and comprises approximately 95% of the total alkaloid content 
(Benowitz et al., 2009).  
 
Nicotine is the primary psychoactive component of tobacco smoke and is responsible for the 
addictive nature of, as well as the soaring incidence of relapse of those who attempt to quit. The 
most extensively used biomarker of nicotine intake is cotinine, which may be measured in blood, 
urine, saliva, hair or nails (Benowitz et al., 2009). The effects of nicotine are exerted on the central 
nervous system (CNS) and other viscera such as the lungs by binding to nicotinic acetylcholine 
receptors (nAChR) where it mimics the biological action of the neurotransmitter acetylcholine 
(Lavezzi et al., 2005). These receptors are members of the ligand-gated ion channels located in the 
brain. They are also said to exist on neurons and non-neuronal tissue such as muscles and immune 
cells (Gallowitsch-Puerta and Tracey, 2005). Both cancerous and normal lung cells have an affinity 
towards nAChR (Pontieri et al., 1996, Maus et al., 1998). Literature suggests that the nicotine and 
 
 
 
 
18 
 
nAChR interface on the surface of rodent bronchiole epithelium, promotes cell proliferation 
(Cattaneo et al., 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.3 Nicotine metabolism 
Nicotine is extensively metabolized into a number of metabolites by the liver. Six chief metabolites 
of nicotine have been identified; however, quantitatively the most essential metabolite of nicotine in 
mammals is the lactam derivative cotinine. In humans, approximately 70-80% of nicotine is 
transformed into cotinine (Benowitz et al., 2009). It is understood that an increased blood flow to 
the liver as well as prompt breakdown of nicotine and cotinine occurs in the mother. Fetal liver 
metabolism of nicotine is lengthy since the enzymatic protection mechanisms of the fetus are not 
fully matured. It is for this reason that a longer half-life of nicotine is thus to be expected (Frank 
and Sosenko, 1987, Walther et al., 1991). Thus, this accounts for more hurried metabolism of 
nicotine and its metabolite cotinine during pregnancy (Dempsey and Benowitz, 2001). This 
observation is therefore validated by the elevated concentrations of nicotine in fetal tissue as 
opposed to maternal blood (Luck and Nau, 1987, Lambers and Clark, 1996). The growing fetal 
lungs as well as other organs are as a consequence exposed to high concentrations of nicotine for a 
Figure 1.5.2: Structure of nicotine and associated tobacco alkaloids (Benowitz and Jacob, 1998). 
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longer period of time and thus its potential destructive effects on cell structure and integrity 
(Kleinsasser et al., 2005).  
 
It should also be noted that proliferating cells at this stage of fetal development are highly 
susceptible to the manipulation by foreign materials such as nicotine (Rehan et al., 2007a). It is 
therefore anticipated that exposure to nicotine during gestation and early postnatal life via the 
mother’s milk may also interfere with the development and growth of the fetus and neonate. Earlier 
studies have shown that the nicotine content of milk of the mother is 2 to 3 times higher than in the 
mother’s plasma (Luck and Nau, 1984a, Dahlstrom et al., 1990). Throughout gestation and 
lactation, nicotine can have a direct effect on cells by decreasing the supply of nutrients to the 
offspring (Guo et al., 2005b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5.3: The main metabolites of nicotine are cotinine and nicotine-N’-oxide. Cotinine is metabolized by 
hydroxylation to trans-3’-hydroxycotinine, N-oxidation to cotinine N-1-oxide, and N-glucuronidation (Pogocki et al., 2007).  
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1.6 Emphysema 
Known as an obstructive lung disease and more specifically falls under the umbrella term of 
chronic obstructive pulmonary lung diseases (COPD). Emphysema is characterized by the distal 
airspaces of the terminal bronchioles that are abnormally and permanently enlarged. This 
enlargement is caused by alveolar wall destruction (Snider et al., 1985) and results in restricted 
airflow and blood oxygenation (Shapiro, 1995). Destruction of the alveolar walls results in enlarged 
alveoli and a decrease in the surface area available for gas exchange.  Emphysema differs from 
restrictive lung diseases such as asthma in that it is an obstructive lung disease; thus individuals 
who suffer from it experience difficulty expelling air from the lungs thus leading to an 
accumulation of air in the alveoli due to damaged elastic tissue and thus an increase in compliance. 
Although the pathogenesis of emphysema is yet to be elucidated, numerous studies have proposed 
that genetic factors may contribute to determining the individual susceptibility to developing 
emphysema (Ito et al., 2005). The development of emphysema has been associated with smoking 
and atmospheric pollution by several scholars (Snider et al., 1985). Factually, emphysema has been 
coupled to extreme lung inflammation caused by chronic inhalation of cigarette smoke and the 
subsequent protease/anti-protease imbalance (Shapiro, 1995). Several studies have proposed that 
connective tissue, specifically elastin, is the primary target of destruction involved in the 
development of emphysema. As a result of elastin destruction, the changes imparted are said to be 
permanent (Mercer and Crapo, 1992).  
 
Two major types of emphysema have been characterized by pathologists which are 
morphologically similar (Friedman, 2008). The first of these is centrilobar emphysema which is the 
most commonly observed emphysema. This form of emphysema is largely associated with chronic 
exposure to cigarette smoke (Pryor et al., 1983, McCusker, 1992). As the name implies, 
“centrilobar” emphysema is distinguished by the collapse of alveolar walls in the central part of the 
acini, originally sparing the peripheral portions of the acinus and lobule. Usually this form of 
emphysema manifests in the upper areas of the lung. Conversely, panlobar emphysema is 
distinguished by the breakdown encompassing all parts of the lobule extending to the periphery and 
is generally more acute in the lower lung areas (Friedman, 2008). Furthermore, it is recognized by 
the enlargement in airspace throughout the acinus and is frequently due to a deficiency in α1-
protease production (McCusker, 1992). 
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Moreover, evidence is accumulating which suggests that alveolar cell apoptosis is implicated in the 
pathogenesis of emphysema (Rangasamy et al., 2004). Given that emphysema is considered as the 
progressive diminishing in alveolar gaseous exchange area, which is highly likely to result in the 
loss of alveolar capillaries, proposals have been made that a possible link between alveolar cell 
apoptosis and a disturbance in cellular and molecular signalling involved in alveolar structural 
maintenance and repair exists. This potential link has extensive implications given that the 
pathogenesis of alveolar destruction induced by cigarette smoke may have mutual features with 
alveolar expansion due to aging (Tuder et al., 2006). 
 
 
1.6.1 Phenotypic variations in fibroblasts 
Fibroblasts play a key role in pulmonary tissue repair and alterations in fibroblast phenotype may 
well be implicated in the pathogenesis of emphysema (Müller et al., 2006).  It has been reported 
that lung fibroblasts from patients with emphysema show a diminished proliferation rate (Holz et 
al., 2004, Nobukuni et al., 2002), altered growth factor response (Noordhoek et al., 2003) and 
reduced number in population doublings in long-term culture (Holz et al., 2004). Nakamura et al. 
(1995) observed that cigarette smoking impeded both fibroblast proliferation and recruitment. This 
impact of cigarette smoke can possibly be attributed to cigarette smoke induced premature aging of 
pulmonary fibroblasts (Nyunoya et al., 2006). Along with clinical observations, these findings offer 
validation to the hypothesis that premature aging of fibroblasts is implicated in the pathogenesis of 
emphysema. This is supported by the fact that increased age is also associated with emphysema 
(Raherison and Girodet, 2009). Bird and colleagues (2003) indeed reported that senescent cells not 
only display changes in morphology and metabolic profile, but also expend their capability to 
divide and respond to mitogenic stimuli. This phenotype is prompted by oxidative stress (Balin et 
al., 2002), in combination with epigenetic manipulations in gene expression. Consequently, since 
fibroblasts contribute to a portion of lung integrity, a senescent phenotype could alter both 
structural maintenance and tissue microbalance (Müller et al., 2006). 
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1.6.2 The proteinase-antiproteinase theory 
Numerous studies have indicated that protease pathogenesis induces several lung diseases, as well 
as asthma and COPD (Demedts et al., 2006), also known as diseases characterized by impaired 
airflow (Eriksson, 1999). Typically, an imbalance between proteolytic and anti-proteolytic 
molecules exists in the lungs of patients who suffer from COPD (Demedts et al., 2006). This results 
in elevated proteolytic activity which triggers the damage of healthy lung parenchyma, prompting 
the development of emphysema. The elevated proteolytic activity may be due to inflammation, 
characterized by the discharge of proteolytic enzymes by inflammatory mediator cells such as 
neutrophils and macrophages, or could otherwise be a result of genetic influences such as an alpha-
1 antitrypsin deficiency (Demedts et al., 2006). 
 
A disturbance in the proteases and anti-proteases balance, by for example oxidants, consequently 
causes the degradation of alveolar walls, thus the progression into emphysema.  Antioxidants does 
so by the stimulation of proteases and the suppression of anti-proteinases. Furthermore, oxidants 
play a crucial role by mediating the inflammatory response by activating the transcription factor 
nuclear factor-kappa beta (NF-B), thus stimulating the transcription of pro-inflammatory genes 
(Demedts et al., 2006). 
 
1.6.3 Oxidant-antioxidant status 
By definition, oxidative stress is the imbalance between the production of reactive oxygen species 
(ROS) and the antioxidant defences in favour of the oxidants (Betteridge, 2000). Under normal 
physiological conditions, antioxidants inactivate the ROS intermediates by scavenging free radicals. 
Oxidative stress cannot only directly cause tissue damage but also influence molecular mechanisms 
that control lung inflammation (Guo and Ward, 2007). Lung epithelia is frequently exposed to 
oxidants either via those generated by normal cellular processes such as those produced by airspace 
phagocytes in lung inflammation, or by direct inhalation of ambient air which contain oxidants such 
as ozone, nitrogen dioxide (Guo and Ward, 2007), cigarette smoke and diesel exhausts (Rahman et 
al., 2006). A significant amount of oxygen passes through the lungs thereby rendering it highly 
susceptible to oxidative stress. It’s for this reason that a sufficient, if not a greater amount of 
antioxidants are required for protection against these exposures (Arab et al., 2002). 
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The primary oxidants present in the lung are reactive oxygen species (ROS) which comprise of 
radicals such as superoxide (O2
-
), hydroxyl (OH) and peroxyl (RO2
-
); non-radicals which include 
hydrogen peroxide (H2O2) and ozone (O3). Oxidants that form part of the reactive nitrogen species 
(RNS45), such as nitric oxide (NO) and nitric dioxide (NO2), as well as the non-radicals such as 
peroxynitrite (ONOO
-
) (Evans and Halliwell, 2001). These oxidative and nitrosative species which 
exert both an indirect and direct effects on tissue, are chief contributors to inflammatory lung injury 
(Lang et al., 2002). Other molecules such as lipid and protein radicals can also  contribute to 
oxidative stress (Musellim et al., 2006). The formation of these oxidants are intensified by the 
exposure to external physical and chemical mediators such as nitrogen oxides, ozone, ionizing and 
ultraviolet radiation, mineral dusts and tobacco smoke (De Paepe et al., 1999). 
 
The major oxidant sources in the lung include eosinophils, alveolar epithelial cells, neutrophils, 
endothelial cells and bronchial epithelial cells. Oxidative stress can bring about the peroxidation of 
membrane lipids, rises in intracellular calcium ions, cytoskeleton disruption, deoxyribonucleic acid 
(DNA) damage, and the reduction of nicotinamide nucleotides (Musellim et al., 2006). As a result, 
this leads to impaired cellular function, induction of apoptosis and the stimulation of dysfunctional 
matrix remodelling (Foronjy and D'Armiento, 2006). It was suggested by Harman (2003) in the free 
radical theory of ageing (FRTA) that ageing or cellular senescence is a consequence of free radical 
reactions (FRR’s). This study supported the findings of Parrinello (2003) who stated that an 
increase in ROS and subsequently oxidative stress participates in the progression into senescence.  
 
Kondoh et al (2005) also illustrated a link between senescence and the glycolytic pathway in that 
glycolysis slows down as the cell becomes older. It is interesting to note that maternal nicotine 
exposure during gestation and lactation slows down glycolysis (Maritz and Harding, 2011b). It was 
indeed suggested that nicotine induces premature lung aging (Maritz and Harding, 2011b, Maritz 
and Mutemwa, 2012). 
 
1.6.3.1 Tobacco smoke as source of oxidants 
Tobacco smoke use or exposure prompts both the airway and parenchymal inflammatory cells to 
generate proteinases, especially elastase, from neutrophils and several metalloproteinases from the 
alveolar macrophages. As a consequence, the antiproteinase defence in the epithelial lining fluid 
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becomes overwhelmed. Majority of lung tissue studies on the pathogenesis of emphysema have 
been centered on the mechanisms involved in chronic injury induced by cigarette smoke to the 
pulmonary parenchyma; notably, perpetual inflammation, oxidative stress, protease-antiprotease 
imbalance, and excessive apoptosis of the alveolar cells (MacNee, 2000, Barnes et al., 2003, Tuder 
et al., 2003). 
 
Antioxidant defences are found both within the fluid epithelial lining of the lung and the lung cells. 
They are the first line of defence (Rahman et al., 2004) and are classed into enzymatic and non-
enzymatic antioxidants. The enzymatic antioxidants of the lung consist of glutamate, cysteine 
ligase, glutathione peroxidise, glucose-6-phosphate dehydrogenase, as well as catalase, superoxide 
dismutase, heme oxygenase-1, peroxiredoxins, glutaredoxins, thioredoxins (Musellim et al., 2006, 
Chu et al., 2005). Non-enzymatic antioxidants include glutathione, α-tocopherol, uric acid, lipoic 
acid and bilirubin, vitamins C and E, and β-carotene (Rahman et al., 2004). Moreover, fluid linings 
in the airways and extracellular spaces of healthy lungs are preserved by millimolar concentrations 
of reduced glutathione (GSH), vitamin C and urates to guard the normal physiological function of 
the lungs. Therefore, in healthy lungs the oxidant-antioxidant levels are balaced in favour of a 
reduced state. A disruption in the equilibrium of the oxidant-antioxidant status in favour of the 
oxidants leads to oxidative stress and is one of the initial incidents that results in inflammatory 
counteraction in the lung (Musellim et al., 2006). 
 
The effect of the oxidants in cigarette smoke is opposed by the antioxidants that occur in the 
epithelial layer of the alveolar walls and in the fluid layer covering these cells (Thorley and Tetley, 
2007). This normal protection ensures that cell aging is normal, but when it becomes depleted such 
as during smoking, this protection is inadequate resulting in type one cell death, increased type 2 
cell proliferation and premature aging of the lungs (Maritz and Harding, 2011b). This can induce 
emphysema over time. It is therefore, important to aim at restoring the anti-oxidant capacity of the 
lungs and thus its ability to protect itself against oxidants in the inhaled air as well as against those 
entering the lungs in the blood. This can partly be achieved through the intake of nutrients that are 
rich in antioxidants such as vitamins A, E and C. 
 
Fruits and vegetables are an excellent source of antioxidants. Substantial interest has been fixed on 
the β-carotene, vitamin C, and vitamin E content of fruits. Although, fruits also contain many other 
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constituents that hold antioxidant activities (Wang et al., 1996). Low molecular weight 
polyphenolic compounds known as flavonoids are extensively distributed in fruits and vegetables 
and a portion of the antioxidant capacity of fruits and vegetables are ascribed to these compounds 
(Hertog et al., 1992, Ortuno et al., 1995). Several flavonoids such as hesperidin, luteolin, 
kaempherol, quercitin, eridictyol, myricetin, lycopene and catechin have been isolated from 
commonly consumed fruits and vegetables such as oranges, lemons, apples, tomatoes, celery, 
broccoli and parsley to name a few. Furthermore, it has been shown to confer antioxidant (Bors and 
Saran, 1987, Bors et al., 1990, Hanasaki et al., 1994, Garg et al., 2001) antihemorrhagic, anti-
inflammatory, anticancer, and antiallergic properties (Das, 1994).  
 
1.6.4. Carotenoids 
Carotenoids are naturally occurring dietary constituents that are contained in most fruits including 
oranges or yellow and green vegetables. Carotenoids are said to exert antioxidant activities and 
prevent free-radical induced cellular damage (Bendich, 1993). Evidence has demonstrated that 
carotenoids are a forthcoming approach in protecting lung function and integrity. According to 
Arab et al. (2002), carotenoids such as lycopene together with other antioxidant vitamins, including 
vitamin C and vitamin E that are present in both the lung epithelial and fluid lining of the lung, may 
provide additional level of defence against oxidative and ozone induced damage. However, 
lycopene is an antioxidant abundantly contained in tomato juice (Di Mascio et al., 1989). Kasagi et 
al. (2006) applied lycopene to evaluate the hypothesis that oxidant-antioxidant imbalance could be 
of importance instead of inflammatory cell influx with the burden of proteinases. 
 
1.6.4.1. Tomato Juice and Lycopene 
Lycopene is a bioactive carotenoid found in many fruits in vegetables and is the primary carotenoid 
in fresh tomatoes and tomato products (Kaplan et al., 1990, Takeoka et al., 2001). It has been 
shown that lycopene confers many beneficial health effects (Giovannucci, 1999) and is said to be 
the most effective biological carotenoid in quenching singlet oxygen (Di Mascio et al., 1989). Since 
lycopene possess antioxidant properties, it has encouraged interest in the tomato as a food with 
possible anticancer characteristics (Giovannucci, 1999). Although β-carotene had been efficient 
against some chemically stimulated cancers, it was not competent in eliminating tumours in the 
respiratory tract (Obermueller-Jevic et al., 2002). Both β-carotene and lycopene is present in lung 
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tissue and thus adds to the possibility that carotenoids are suitable defence mechanisms against 
oxidative stress (Takeoka et al., 2001). 
 
Research done by Agarwal et al. (2001) showed that the consumption of tomato products conferred 
protection against oxidative damage to serum lipids, low density lipoproteins (LDL’s), proteins, 
lipids, and lymphocyte DNA. Also noted from their study was that lycopene supplementation 
causes a decrease in DNA damage, which as suggested, might play a considerable role in lowering 
the development of cancer by  lessening the oxidation of DNA and proteins (Arab et al., 2002). 
Furthermore, preceding literature also discloses that an increase in oxidized proteins have a vital 
role in the development of chronic diseases as well as the process of aging. Several proteins 
function as metabolic enzymes and as a result, their oxidative damage may therefore cause a loss in 
its particular function (Stadtman, 1992, Hu, 1994). 
 
As demonstrated by Liu et al. (2006), purified lycopene was shown to act concomitantly with other 
bioflavonoids like glabridin, the phenolic compounds carnosic acid and rosmaniric acid along with 
garlic in impeding in vitro LDL oxidation. Literature on the sole antioxidative effects of lycopene 
in a biological organism is limited (Mein et al., 2008). However, studies report that considerable 
inhibition of N-methyl-N-nitrosourea-testosterone induced carcinogenesis in male Wistar-unilever 
rats following tomato powder intake (13 mg/lycopene/kg diet), while no differences were observed 
subsequent to lycopene supplementation per se (161 mg/lycopene/kg diet) (Basu and Imrhan, 
2007). This implies that lycopene together with other antioxidants, present in tomatoes, may be 
more effective in deterring lipid peroxidation as opposed to lycopene in isolation. This suggests that 
these nutrients in fruit and vegetables are working together for the best effect. In isolation it 
becomes ineffective. 
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1.7 Cellular senescence 
Biological aging comprises of an array of molecular, cellular and structural modifications founded 
on several mechanisms. Although conventionally associated with chronological age, biological 
aging can occur earlier in life, with partial dependence on the individual’s chronological age 
(premature aging) (Balcombe and Sinclair, 2001). Cellular senescence has been defined as the state 
of constant arrest in the G1/G0 phase of the cell cycle. During this phase primary somatic cells 
possess a complete irreversible loss of their replicative capacity (Hayflick, 1965). 
 
According to Hayflick and Moorhead (1961, 1965), in vitro studies have shown that the 
proliferation of normal human lung and skin fibroblasts are curbed to a certain number of divisions 
and that the replicative capacity of the cells deteriorate with age. The maximum number of 
divisions for cells is known as the “Hayflicks limit” and ranges between 50 to 70 divisions in tissue 
culture. The instant the Hayflicks limit is achieved, the cells will cease to divide and enters a type 
of cell arrest known as replicative senescence (Serrano and Blasco, 2001). As a result, the cells will 
undergo a series of functional, biochemical and morphological changes which are indicative of 
cellular aging (Dimri et al., 1995), including the loss of proliferative ability in otherwise viable cells 
(Karrasch et al., 2008). The incidence of acute, self-limiting lung diseases, prior tobacco 
consumption and exposure to environmental pollutants in elderly people makes it challenging to 
solely distinguish pulmonary alterations that could be ascribed to ‘normal aging’ (Dyer and 
Stockley, 1999). Throughout a lifetime the human lung is subjected to a multitude of factors 
capable of altering lung structure and function by enhancing the aging of the lung. It is for this 
reason that it is highly likely that all these factors may enhance the rate at which age associated 
deterioration of lung structure and function occur (Dyer and Stockley, 1999). 
 
 The notion of the ‘Hayflick limit’ suggests that normal somatic cells possess a cell division 
counting mechanism or ‘clock’(Hayflick and Moorhead, 1961). According to the telomere 
hypothesis of senescence, the tallying process is progressive with telomere shortening which occurs 
during cell division (Olovnikov, 1973).  Telomeres form protective caps at the terminus of the 
chromosome which prevents it from being identified as double-strand (ds) breaks as well as 
preventing the DNA ends from degradation or recombination (Chen et al., 2001, Lange et al., 
2005). Given that the chromosome does not possess the ability to duplicate end of linear molecules, 
telomeres shorten with each cell division (Blasco, 2005). Eventually, telomeres reach a 
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considerably short length and appear as ds DNA breaks. These ds DNA breaks stimulates the 
expression of the tumour suppressor protein p53 resulting in telomere-initiated senescence or 
apoptosis (de Lange, 2005, Zglinicki and Martin-Ruiz, 2005). The telomere is lengthened by 
telomerase, a ribonucleoprotein with DNA polymerase activity (Greider and Blackburn, 1985). By 
using a generation of telomere-deficient mice, Blasco et al. (1997) demonstrated that telomerase is 
the most vital cellular activity which accounts for the maintenance of telomere length. Thus, rapid 
cell division, such as those induced by cellular damage, may result in an increase in the number of 
senescent cells in, e.g., the lungs. This may make the lung more susceptible to disease related to 
aging. 
 
Senescent cells assume distinct, flat and distended cell morphology; this appearance can be used to 
differentiate between senescent cells and non-senescent cells (Rattan, 1995). Senescent cells also 
display a senescence associated β-galactosidase activity (Dimri et al., 1995) which may be 
suggestive of an increased lysosomal-mass (Lee et al., 2006). 
 
1.7.1 The relationship between senescence and apoptosis 
Apoptosis is a distinct form of programmed cell death typified as the loss of cell function and 
prompt morphological changes, culminating in cell death without inflammation (Del Riccio et al., 
2004). Apoptosis and senescence takes place during normal development and growth of cells and 
organisms. Hengartner (1995) proposed that senescence is a crucial cellular mechanism in the 
maintenance and preservation of physiological equilibrium within a system. 
 
Senescent cells are found to be arrested in the G1/G0 phase of the cell cycle. As a result these can 
no longer respond to growth factors and become irreversibly resistant to apoptosis (Kong et al., 
2011). It is still unclear what determines if a cell undergoes apoptosis or senescence. Although cells 
are generally capable of both, these processes appear to be absolute (Campisi and D'Adda Di 
Fagagna, 2007). Cell types seem to be a factor as damaged fibroblast and epithelial cells tend to 
undergo senescence whereas damaged lymphocytes tend to undergo apoptosis. It has been reported 
that attempts to hinder senescence by telomerase overexpression, does not impede cellular 
senescence but rather protects cells from undergoing apoptosis (Gorbunova et al., 2002, Massard et 
al., 2006). Similarly, manipulations of the expression levels of Bcl-2 or caspase inhibition may 
result in cells that typically undergo apoptosis to enter senescence (Rebbaa et al., 2003, Nelyudova 
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et al., 2007). Furthermore, these studies strongly suggest a complex cross regulation between 
apoptosis and senescence (Seluanov et al., 2001). 
 
1.7.2 The role of senescence in cell proliferation 
Cell proliferation is defined as the increase in cell number as a result of cell growth or cell division. 
The balance between cell proliferation and apoptosis is vital normal development and tissue-size 
homeostasis in the adult (Guo and Hay, 1999). It was found by Nyunoya and colleagues (2006) that 
exposure to cigarette smoke ceased the proliferation of lung fibroblasts and upregulated two 
pathways allied to cell senescence, p53 and p16-retinoblastoma protein (pRB) pathways. They also 
observed that while a single exposure to cigarette smoke inhibited normal fibroblast proliferation, 
multiple or incessant exposure to cigarette smoke shift cells into an irreversible state of senescence. 
This inability to repair lung injury may be a fundamental feature of emphysema (Nyunoya et al., 
2006). 
 
1.7.3 The relationship between Apoptosis and proliferation and their role in  Emphysema 
Numerous threads of evidence relate apoptosis to proliferation. Cellular proliferation, 
differentiation, and death are essential processes in multicellular organisms, and play a role during 
developmental phases as well as aging to maintain cell populations in tissues, thus contributing to 
homeostasis. Originally, uninhibited proliferation can be coupled with an excessive level of 
apoptosis. Several latent oncogenes such as c-Myc, seem to prompt apoptosis, which implies that 
crosstalk between the cell proliferation and apoptosis pathways is present (Evan et al., 1992). 
Previous studies have shown that emphysematous lungs are linked with amplified levels of 
apoptosis in both alveolar epithelial and endothelial cells (Yokohori et al., 2004). Consequently, the 
integrity of the alveolar wall structure in the lungs become diminished and due to the loss of cells 
by apoptosis. To counterbalance the alveolar loss, cellular proliferation will therefore escalate 
(Tsuji et al., 2006). Supporting studies have observed that patients with emphysematous lungs had 
increased levels of proliferation in comparison to those with normal lungs (Imai et al., 2005). The 
latter stands in agreement that a direct correlation between apoptosis and cellular proliferation in 
the pathogenesis of emphysema subsists.  
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Hence, based on the cited literature, the aims of this study were to determine: 
 Whether maternal nicotine exposure during pregnancy, and until weaning was completed at 
day 21, affects the phases of fetal- and postnatal lung development 
 Whether maternal nicotine exposure induces premature aging in the lungs of the offspring 
 What the role of fibroblasts are in premature aging in the lungs of the offspring 
 Whether tomato juice supplementation would avert premature aging in the lungs of the 
offspring 
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CHAPTER TWO 
Methods and Materials 
 
2.1 Animal preparation and ethical clearance 
White virgin female rats (Wistar descendants) were used in the present study. Animals were sheltered in 
the animal rooms at the Department of Medical Biosciences of the University of the Western Cape. 
Ethical clearance for this study has already been approved by the Ethical Committee of the University 
of the Western Cape in accordance to the guidelines of the Medical Research Council for Animal Care. 
Animals were fed a stock diet (Epol rat cubes and water as required) throughout the study. Room 
temperature was kept at 22˚±1˚C and a day-night cycle of 12 hours (06:00 – 18:00) was maintained. 
 
2.2 Treatment of animals 
Animals were mated overnight and subsequently randomly assigned to a control and three different 
experimental groups. At least 6 female rats were assigned to each group. The pregnant experimental 
animals were divided into 4 groups:  
 
 Group 1 received 1 mg of nicotine subcutaneously/kg body weight/day. 
 Group 2 received tomato juice only.  
 Group 3 received both nicotine (1 mg/kg body weight/day) and tomato juice. 
 Group 4 was the control, receiving saline injections subcutaneously where the volume of 
saline was determined by the initial body weight of the mother.  
 
The treatment of all four groups began as soon as the animals were mated and was terminated at 
weaning when the offspring that were born to these mothers, were 21 days old. It is important to note 
that the offspring were not treated with nicotine, saline or tomato juice. Only the mothers received 
nicotine, saline, or tomato juice. Since nicotine crosses the placenta and occurs in the milk of smoking 
mothers (Luck and Nau, 1984b), the offspring would therefore be exposed to nicotine only via the 
placenta and the mother’s milk. Nicotine doses were not changed as the body weights of the animals 
increased during pregnancy; it remained standard according to the initial body weight of the female rats 
before mating. Nicotine doses were administered via subcutaneous injections with a 1ml tuberculin 
syringe. 
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All Gold Tomato juice containing 5.3 mg lycopene/100 ml was diluted 50/50 with distilled water on a 
daily basis due to its content being too viscous to move though the drinking bottles. It was freely 
available for the animals to drink from 200 ml glass water bottles. The water and tomato juice intake 
was measured daily at a set time, and the average intake was recorded per week. The lycopene intake 
was calculated based on the tomato juice intake by the animals and recorded as the average weekly 
intake (mg/100 g body weight/week). Apart from lycopene (5.3 mg/100 ml tomato juice), the tomato 
juice also contains protein (0.8 g/100 ml), carbohydrates (3.4 g/100 ml), fibre (0.55 g/100 ml), and 
sodium (200 mg/100 ml). The pregnant rats within each of the experimental groups were weighed on a 
weekly basis to monitor any changes in their body weights and to determine if any abnormalities occur 
in body weight due to their different treatments. After birth the number of rat pups per litter was kept 
between 8 and 10 pups to ensure that the nutrient supply from the mother was adequate to support the 
normal growth and development of the offspring. 
 
  
Figure 2.2: Demonstration of the rat model representing the animals exposed to nicotine, tomato juice and a 
combination of nicotine and tomato juice in utero. The F0 generation was mated to produce the F1 generation. 
The F1 offspring were exposed via the mother’s placenta and breast milk.  
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2.3 Lung extraction procedure 
The lungs were extracted from weaned pups at four different age groups namely postnatal days 14, 21, 
42 and 84. Four litters of pups were taken from each of the 4 age groups, and the lungs of at least 3 pups 
from each of the litters were used. The rat lungs were fixed in 10% buffered formalin solution after the 
removal from the thorax. The following reagents were used to make up 10% buffered formalin solution: 
 
 Formaldehyde         100 ml 
 Distilled water         900 ml 
 Sodium dihydrogen phosphate, monohydrate (NaH2PO4.H2O)  4 g 
 Disodium hydrogen phosphate, anhydrous (Na2HPO4)  6 g 
 
Before the rats were sacrificed, they were weighed and the weight was recorded. The chest 
circumference and the crown-rump length were subsequently measured and recorded. To remove 
lung tissue, the offspring were anaesthetized with an intraperitoneal injection of Sodium 
Pentobarbitone (90 mg/kg/BW). Once the rats were completely unconscious, the thoracic cavity 
was carefully opened. Special care was taken to prevent damage to the lungs. Thereafter, the 
trachea was surgically cannulated and the diaphragm punctured. Lungs that were damaged during 
the dissection were discarded. The fixative (10% buffered formalin, pH 7.2) was allowed to flow 
into the lungs via the trachea while a transpulmonary pressure gradient of 25 cm fixative was 
maintained. After 30 minutes the lungs were ligated at the hilum of the lungs and removed via 
excision en bloc for morphologic and morphometric studies. The lungs were each separately 
labelled and stored in buffered formalin (pH 7.2). Buffered formalin solution was made up of 4 g 
Sodium Phosphate (Anhydrous) and 6 g Sodium Phosphate (dehydrogenous) added to 900 ml 
distilled water. Once the chemicals were dissolved in the water, 100 ml Formaldehyde solution was 
added to make up a 1000 ml buffered formalin solution. 
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2.4 Determination of lung  
Lung volumes were measured by the fluid displacement method as described by Scherle (1970), 
whereby a 100 ml beaker containing buffered formalin at a pH of 7.2 was weighed on a scale, and 
then zeroed. With the support of a surgical forceps, the extracted lung was then immersed in the 
beaker at a level of buoyancy, and the final lung volume was determined. Lung volumes were 
determined before and after the 24-hour fixation period to detect shrinkage. 
 
2.5 Lung tissue processing 
An automatic tissue processor was used. Care was taken as not to damage any of the lung tissue. 
For each lung, the left inferior lobe was gently cut off with a scalpel and perfectly placed in a 
properly labelled cassette. When all the cassettes containing the lung tissue were ready, they were 
placed into the tissue processing rack of the automatic tissue processor. The processor was 
programmed so that the lungs to be processed underwent an 18 hour cycle as follows: 
 
Table 2.5.1: Illustration of the tissue processing procedure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
AGENT TIME 
Dehydration Process  
1. 70% Ethanol 
2. 80% Ethanol 
3. 90% Ethanol 
4. Absolute Ethanol I 
5. Absolute Ethanol II 
2 hours 
2 hours 
2 hours 
2 hours 
2 hours 
2 hours 
Deparaffination Process  
6. Xylene bath I 
7. Xylene Bath II 
2 hours 
2 hours 
Tissue Embedding Preparation  
8. Wax bath I 
9. Wax bath II 
2 hours 
2 hours 
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2.6 Tissue embedding and microscopy 
Tissues were manually removed from cassettes in order to begin the tissue embedding procedure. 
Lung tissue was carefully aligned and fixed into a mould block using warm wax to fill the mould. 
The mould hardened on an ice plate utilizing a tissue embedding machine. Tissue blocks were 
trimmed at right angles to enable accurate morphometric measurements. The paraffin tissue blocks 
were then cut with a microtome into sections of 5 μm for the tinctorial stains and 3 µm for 
immunohistochemistry staining for further microscopy. Every third section was used for 
morphology and morphometric evaluation. This prevented double counting of tissue constituents.  
Once the sections were cut, they were floated on a warm water bath, and was then shifted onto a 
glass microscopic slide for further staining processes. Once slides were dried, it was placed in an 
oven at 60°C for 30 minutes to allow fixation of lung tissue to the slide. All slides were initially 
examined to eliminate sections with evidence of inadequate preparation. A total of 32 slides for 
each postnatal group (day 14, 21, 42, 84) were prepared and equally divided amongst each of their 
experimental groups (control, tomato juice, nicotine, and a combination of nicotine and tomato 
juice).  
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2.7 Tinctorial stains 
2.7.1 Hematoxylin and Eosin (H&E) 
 Principle 
This stain is a gold standard and is practiced in every histology laboratory. It will be used for 
morphometric analysis as well as morphology of the alveoli, alveolar wall cells as well as 
surrounding structures. 
 
Table 2.7.1: Hematoxylin &Eosin Staining Protocol 
  
CHEMICAL SOLUTION TIME 
Deparaffination and Rehydration  
1. Xylene Bath I 
2. Xylene Bath II 
3. Absolute Ethanol I 
4. Absolute Ethanol II 
5. 90% Ethanol 
6. 80% Ethanol 
7. 70% Ethanol 
5 mins 
5 mins 
5 mins 
5 mins 
5 mins 
5 mins 
5 mins 
Haematoxylin Staining  
8. Haematoxylin 
9. Rinse in tap water 
10. Scott’s tap water 
11. 1% Acid Alcohol- destaining agent 
15 mins 
 
2 mins 
2 mins 
Eosin Staining and Dehydration  
12. Eosin- counter stain 
13. Rinse in tap water 
14. 80% Ethanol 
15. 90% Ethanol 
16. Absolute Ethanol 
17. Xylene Bath I 
18. Xylene Bath II 
19. Mount for observation using DPX  and slide coverslips 
3 mins 
 
2 mins 
2 mins 
2 mins 
2 mins 
2 mins 
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2.7.2 Masson’s Trichrome (Connective tissue) 
 Principle 
The Masson’s Trichrome Stain employs three dyes, selectively staining erythrocytes, fibrin, 
collagen fibers and muscle tissue. The universal rule in trichrome staining is that tissues that are 
less porous are coloured by the smallest dye molecule; with the penetration of a larger dye 
molecule, it will always do so at the expense of a smaller dye molecule.  
 
Table 2.7.2: Masson’s Trichrome Staining Protocol 
 
 
 
 
  
CHEMICAL SOLUTION TIME 
Deparaffination and Rehydration  
1. Xylene Bath I 
2. Xylene Bath II 
3. Absolute Ethanol I 
4. Absolute Ethanol II 
5. 90% Ethanol 
6. 80% Ethanol 
7. 70% Ethanol 
8. Wash in tap water 
9. Quick dip in dH2O 
3 mins 
3 mins 
3 mins 
3 mins 
3 mins 
3 mins 
3 mins 
3 mins 
3 mins 
Hematoxylin Staining  
10. Weigerts Hematoxylin 
11. Tap water 
12. Rinse in dH2O 
5 mins 
3 mins 
Masson’s Fuchsin Ponceau-Orange G (MPFOG)  
13. Counterstain with MFPOG 
14. Rinse in Acetic acid water 
30 mins 
1 min 
Phosphotungstic Acid  
15. Mordant in Phosphotungstic acid solution 
16. Rinse in acetic acid water 
5 mins 
1 min 
Light Green Staining  
17. Light Green solution 
18. Treat with acetic acid water  
20 mins 
5 mins 
Dehydration   
19. 80% Ethanol 
20. 90% Ethanol 
21. Absolute Ethanol 
22. Xylene Bath I 
23. Xylene Bath II 
24. Mount for observation using DPX and coverslips 
2 mins 
2mins 
2 mins 
2 mins 
2 mins 
2 mins 
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2.8 Immunohistochemistry (IHC) 
All immunohistochemistry was done using the Bond
TM
 Polymer Refine Detection (Catalogue No. 
DS9800) from Leica Biosystems Ltd. This detection system is for in vitro diagnostic use. Bond 
Polymer Refine Detection is a biotin-free, polymeric horseradish peroxidase (HRP)-linker antibody 
conjugate system for the detection of tissue-bound mouse and rabbit IgG and some mouse IgM 
primary antibodies. It is intended for staining sections of formalin-fixed, paraffin-embedded tissue 
on the Bond
TM
 automated system. Immunohistochemical techniques can be used to demonstrate the 
presence of antigens in tissue and cells. Bond Polymer Refine Detection utilizes a novel controlled 
polymerization technology to prepare polymeric HRP-linker antibody conjugates. The detection 
system avoids the use of streptavidin and biotin, and therefore eliminates non-specific staining as a 
result of endogenous biotin. 
 
Bond Polymer Refine Detection works as follows: 
The specimen is incubated with hydrogen peroxide to quench endogenous peroxidase activity. 
1. A user-supplied specific primary antibody is applied. 
2. Post Primary IgG linker reagent localizes mouse antibodies. 
3. Poly-HRP IgG reagent localizes rabbit antibodies. 
4. The substrate chromogen, 3,3’-Diaminobenzidine tetrahydrochloride (DAB), visualizes the 
complex via a brown precipitate. 
5. Hematoxylin (blue) counterstaining allows the visualization of cell nuclei. 
 
2.8.1 Protocol: Leica Bond Max staining protocol  
A standard protocol was used for all the antibodies mentioned in the present study. Table 2.8.1 
illustrates the method for IHC applied staining. 
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Table 2.8.1: Illustrates the IHC staining protocol as provided by Leica Biosystems Ltd 
Step Type Incubation Time Temperature Dispense Type 
1 Peroxide Block 5 min Ambient selected vol. 
2 Bond Wash Solution 0 min Ambient selected vol. 
3 Bond Wash Solution 0 min Ambient open 
4 Bond Wash Solution 0 min Ambient selected vol. 
5 Primary Antibody 15 min Ambient selected vol. 
6 Bond Wash Solution 0 min Ambient selected vol. 
7 Bond Wash Solution 0 min Ambient selected vol. 
8 Bond Wash Solution 0 min Ambient selected vol. 
9 Post Primary 8 min Ambient selected vol. 
10 Bond Wash Solution 2 min Ambient selected vol. 
11 Bond Wash Solution 2 min Ambient selected vol. 
12 Bond Wash Solution 2 min Ambient selected vol. 
13 Polymer 8 min Ambient selected vol. 
14 Bond Wash Solution 2 min Ambient selected vol. 
15 Bond Wash Solution 2 min Ambient selected vol. 
16 Deionized Water 0 min Ambient selected vol. 
17 Deionized Water 0 min Ambient selected vol. 
18 Mixed DAB Refine 10 min Ambient selected vol. 
19 Deionized Water 0 min Ambient selected vol. 
20 Deionized Water 0 min Ambient selected vol. 
21 Deionized Water 0 min Ambient selected vol. 
22 Hematoxylin 5min Ambient selected vol. 
23 Deionized Water 0 min Ambient selected vol. 
24 Deionized Water 0 min Ambient selected vol. 
25 Deionized Water 0 min Ambient selected vol. 
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2.8.2 Staining for fibroblasts and Type II alveolar epithelial cells (Vimentin) 
 Principle 
Vimentins are class-III intermediate filaments found in numerous non-epithelial cells, especially 
mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, 
either laterally or terminally. Vimentin is highly expressed in fibroblasts, some T-and B-
lymphocytes, in many hormone-dependent mammary carcinoma cell lines, and little or no 
expression in Burkitt’s lymphoma cell lines. Vimentin is localized in the cytoplasm and found in 
connective tissue and the cytoskeleton. Since they are expressed in a highly developmentally-
regulated fashion; vimentin is the major cytoskeletal component of mesenchymal cells. Because of 
this, vimentin is often used as a marker of mesenchymally-derived cells or cells undergoing 
an epithelial-to-mesenchymal transition (EMT) during both normal development and 
metastatic progression. Furthermore, studies done by Fujino and co-workers (2011) showed that 
AT11 cells that expressed surfactant protein A (SP-A) and surfactant protein D (SP-D), were also 
positive for vimentin. Therefore, in the current study I was able to stain for pulmonary fibroblasts 
and concomitantly stain for Type II alveolar cells. 
 
 Method 
 Tissue sections of 3 μm in thickness were cut and placed on slides.  
 The tissue was dried in a 60°C oven for 1-2 hours.  
 Slides was deparaffinised in 2 washes of Xylene for 5 minutes each and rehydrated 
in a series of graded alcohol.  
 Using the Leica Bond Max staining protocol F (Table xxx), the primary antibody; 
Anti-Vimentin antibody [EPR3776]-Cytoskeleton Marker (Catalogue No. ab92547) 
was used to stain fibroblast activity at a 1/500 dilution as suggested by Abcam
® 
for 
IHC-P. 
 Mount with DPX and slide coverslips. 
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2.8.3 Staining for senescence (β-galactosidase) 
 Principle 
The purpose for this stain is to detect senescent cells in the alveolar walls of the lungs. Senescence-
associated beta-galactosidase (SA-β-gal) is a hydrolase enzyme that catalyzes the hydrolysis of β-
galactosides into monosaccharides only in senescent cells. It is localized in the cytoplasm and 
coded by a gene (lacZ) in the lac operon of Escherichia coli (E. coli). This metalloenzyme has three 
enzymatic mechanisms. First, by cleaving the disaccharide lactose into glucose and galactose, this 
can then enter glycolysis. Second, it can catalyze the transgalactosylation of lactose to allolactose, 
and, third, the allolactose can be cleaved into the monosaccharides. It is the allolactose that binds to 
the lacZ repressor and generates the positive feedback loop that regulates the amount of β-
galactosidase in the cell. This will indicate cellular senescence. 
 
 Method 
 Tissue sections of 3 μm in thickness were cut and placed on slides.  
 The tissue was dried in a 60°C oven for 1-2 hours.  
 Slides was deparaffinised in 2 washes of Xylene for 5 minutes each and rehydrated 
in a series of graded alcohol.  
 Using the Leica Bond Max staining protocol F (Table xxx), the primary antibody; 
Anti-beta Galactosidase antibody [DC1 4C7] (Catalogue No. ab116) was used to 
stain senescent cells at an assay dependent concentration as set out by Abcam
® 
for 
IHC-P. In the present study a 1/250 dilution was used. 
 Mount with DPX and slide coverslips. 
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2.8.4 Staining for proliferation (PCNA) 
 Principle  
PCNA (Proliferating Cell Nuclear Antigen) was previously known as cyclin. PCNA is a 36 kDa 
nonhistone protein found in the nucleus that plays a role in the initiation of cell proliferation by 
mediating DNA polymerase. PCNA levels are elevated in the S, G2, and M phases of cell mitosis in 
normal and malignant tissues. PCNA expression has a broad correlation with mitotic activity and 
can be used as a marker for cell proliferation. PCNA has proven useful for proliferative studies of 
normal and neoplastic tissues both in vivo and in vitro.  
 
 Method 
 Tissue sections of 3 μm in thickness were cut and placed on slides.  
 The tissue was dried in a 60°C oven for 1-2 hours.  
 Slides was deparaffinised in 2 washes of Xylene for 5 minutes each and rehydrated 
in a series of graded alcohol.  
 The Anti-PCNA antibody [PC10] (Catalogue No. ab29) was used to stain senescent 
cells at a dilution of 1/10000, heat mediated antigen retrieval with citrate buffer pH 6 
before commencing with the IHC staining protocol F (Table 2.8.1). 
 Mount with DPX and slide coverslips. 
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2.8.5 Staining for apoptosis (AIF) 
 Principle 
Apoptosis inducing factor (AIF) is a positive intrinsic regulator of apoptosis (caspase-dependent 
pathway) by causing both chromatin condensation and DNA fragmentation. Probable 
oxidoreductase that has a dual role in controlling cellular life and death; during apoptosis, it is 
translocated from the mitochondria to the nucleus to function as a proapoptotic factor in a caspase-
independent pathway, while in normal mitochondria, it functions as an antiapoptotic factor via its 
oxidoreductase activity. 
 
 Method 
 Tissue sections of 3 μm in thickness were cut and placed on slides.  
 The tissue was dried in a 60°C oven for 1-2 hours.  
 Slides was deparaffinised in 2 washes of Xylene for 5 minutes each and rehydrated 
in a series of graded alcohol.  
 Using the Leica Bond Max staining protocol F (Table xxx), the primary antibody; 
Anti-AIF antibody [E20] - Mitochondrial Marker (Catalogue No. ab32516) was 
used to stain apoptotic cells at an assay dependent concentration as set out by 
Abcam
® 
for IHC-P. In the present study a 1/500 dilution was used. 
 Mount with DPX and slide coverslips. 
 
 
2.9 Morphology and Morphometry 
The following parameters were used to determine the influence of maternal exposure to nicotine, 
tomato juice only or both nicotine and tomato juice on lung development in the F1 offspring. For 
morphometry, samples were taken from the left and the right lobes of the lung. Large airways and 
blood vessels were avoided when determining the measurements. The mean alveolar intercept (Lm) 
was determined as described by Weibel and Knight (Weibel, 1963). The alveolar (Va) and 
parenchymal (Uksusova and Nizovtsev, 1982) density were determined as described by Bolender 
and colleagues. At least 25 randomly selected, non-overlapping fields from each section were 
analysed (Bolender et al., 1993). Seventy five fields from each animal were counted. Alveolar wall 
thickness was determined as described by Bolender et al (1993).  
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The morphometric techniques used in this study included:  
 Volume Density (Vt and Va) 
 Mean Linear intercept (Lm)  
 Alveolar wall thickness (Tsept) 
 
2.9.1 Volume Density (Vt and Va)  
 Principle 
Alveolar volume is indicative of the size of the alveolus and therefore the volume of air that 
occupies it. It is expected that in alveoli with larger volumes, the total surface area for gaseous 
exchange in the lung would be reduced. This would also mean that there would be a possibility of a 
reduced alveolar surface area for gaseous exchange and fewer alveoli. According to Blanco et al 
(1991), the average size of an individual alveolus increases with age. 
 
 Method 
The alveolar air volume density (Va) and alveolar tissue volume density (Vt)  (Uksusova and 
Nizovtsev, 1982) were determined as illustrated by Bolender et al. (1993). A 122-point eyepiece 
graticule was used at 100 x magnifications for the point counting technique which helped in 
determining the alveolar air volume density Va and Vt. 
 
 Determination of Vt 
A 10x eyepiece and a 10x objective were used to obtain a total magnification of 100x. Two blocks 
were taken from the upper lung lobe, 1 from the middle lobe and two from the lower lobe. Non-
parenchymal tissue included bronchus and blood vessels which had a diameter of >1.1 mm. The 
alveoli that were found within the graticule and those that touched the lower and right borders of 
the graticule were included. The alveoli were excluded from the count including those that were 
outside the square on the upper and the left side of the graticule. Furthermore, the fields surround 
by non-parenchymal tissue was excluded from the counts. At least 5 randomly selected non-
overlapping fields were analysed for each slide. 
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The alveoli that contributed to the count included:  
 Those that were found within the graticule, and  
 Those that touched the right lower borders of the graticule.  
 
The alveoli that did not contribute in the count included:  
 Those found outside the square on the upper left side of the graticule.  
 Areas that contained non-parenchymatous tissue were excluded from the counts. 
At least 5 randomly selected non-overlapping fields per slide were analysed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.9.1: Illustration of the eyepiece grid used for point counting. The grid contains 122 points (Where lines 
cross, blue arrow). Points (blue arrows) that are over lung tissue (red arrows) were counted and the tissue density 
(Vt) calculated. In this example are 3 “hits” (red arrows) out of 122 points. Thus: 3/122x100 = 2.46% 
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2.9.2 The Mean Linear Intercept (Lm)  
 Principle 
The Mean linear intercept (Lm), is the average distance found between alveolar walls and indicates 
the diameter of the alveolus (Dunnill, 1962). During normal lung maturation, the Lm increases with 
decreasing air-tissue interface. In microscopic emphysema however, the Lm has been observed to 
increase, indicating alveolar wall destruction and an increase in alveolar volume. Increase in Lm is 
indicative of a decrease in surface area available for gaseous exchange. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Figure 2.9.2: Illustration of a field (N) with a line drawn with the aid of Image J. The length of the line (red 
arrow) is determined by Image J and the number of intercepts (black arrows example of intercepts) counted for 
determination of Lm.  
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Determination of Lm:  
Equation: Lm = N x L/m  
 
Where: N = number of fields counted  
  L = length of cross line (see red arrow)  
  m = sum of all intercepts      
Example of the calculation: 
Field Number (#) of intercepts Length of cross line 
1 20 820.088 
2 26 622.048 
3 35 868.021 
4 29 760.011 
5 32 994.002 
 
 Total # of intercepts: 142        
 Sum of all intercepts: 4064.17 
 Thus: Average = 4064.17/5 
    = 8.12.83 
 Where: 
  812.84 µm = average length of the cross line 
  142 = total # of intercepts 
 
 Lm  = N x L/m 
        = 5 x 812.83/142 
         = 28.62 µm 
 
An intercept is where the cross line passes through the alveolar wall. Crossing an alveolar wall = 2 
intercepts. The line just touches an alveolar wall = 1 intercept. The number of alveolar intercepts 
(m) was determined using an eyepiece micrometer at 100x magnification. For each slide 5 fields 
were used to determine the mean linear intercept. 
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The following alveolar walls contributed to the intercept count:  
 Those that touched without crossing the left side of the vertical line,  
 Those that touched without crossing the upper end of the horizontal line, and  
 Those that intercepted the cross hairs.  
 
Cut blood vessels were each counted as half an intercept.  
 
Structures and Alveolar walls that did not contribute to the mean linear intercept included:  
 Those that touched but not cross the right border of the vertical arm, and  
 Those that touched but not cross the lower border of the horizontal arm. 
 
 
2.9.3 Interalveolar Septal Thickness (Tsept) 
 Principle  
The interalveolar septal thickness (Tsept) is the distance between alveoli that are adjacent to each other 
or the thickness of the wall of the alveoli between adjacent alveoli. Tsept is determined by utilizing the 
point counting and linear intercept method as described by Weibel (1963). The Weibel no. 1 graticule at 
100x magnification will be used to determine the number of points on the alveolar septum and number 
of alveolar intercepts. For each slide, 5 non-overlapping fields will be were randomly selected and 
analysed for each slide. 
 
 Determination of Tsept 
 Equation: Tsept = z x Pse/2x Ise,  
 Where: z = lengths of lines on graticule (um)  
  Pse = points on alveolar walls  
  Ise = number of intercepts of alveolar walls 
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2.9.4 Lung Compliance (CSt) 
An estimate of the lung compliance is a measure of the ability of the lung to stretch when a volume of 
air is inhaled, and its ability to recoil when it is exhaled. Lung compliance was determined by 
determining the volume of the lungs of the F1 control and experimental groups at different ages at a 
constant transpulmonary pressure of 25 cm H2O. 
 
 Determination of lung compliance 
Equation: Lung Compliance = Lv/p ÷ BW  
 
Where: Lv = Lung Volume of Animal  
 P = 25 cm H2O (pressure constant)  
 BW = Body Weight of Animal  
 
 
2.9.5 Quantification of: Cellular proliferation, cellular senescence, pulmonary fibroblasts, 
 and type II alveolar cells (ATII)  
 Method 
The number of senescent and other cells was expressed as the number of senescent (or other cells) 
cells /100 μm of alveolar wall. The total number of a specific cell type per length of alveolar wall 
was determined by using the Image J software application. Pictures were taken at 400x 
magnification and used for determining cell numbers. For each slide, 5 randomly selected non-
overlapping fields were used and a freehand line was drawn along the alveolar wall, where the line 
started at, for example a senescent cell and ended at a senescent cell. The number of a specific cell 
type occurring between the start and the end points of the line was counted and the number of cells 
was expressed as number of the specific cell type /100 μm of the alveolar wall.  Slides of lung 
tissue of between 3 and 5 animals from at least 3 litters were used. 
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Specific cell types were calculated as follows; 
 E.g. Fibroblasts/100 µm =N*100/L 
 Where: N = number of fibroblasts counted 
       L= length of area containing fibroblasts (see red line) 
 
Fibroblast number = 6*100/340.645 
    =1.76 cells/100 µm 
 
This method was used to quantify and calculate the cellular proliferation, cellular senescence, type 
II alveolar cells, and fibroblasts respectively. 
Figure 2.9.5: Illustration of the quantification of cells per length of alveolar wall using Image The red lines 
indicate the alveolar wall where cells (e.g., fibroblasts) were counted The arrows indicate the starting point and 
end points which are, e.g. fibroblasts. All fibroblasts between those cells were counted. Both the starting and 
final cells were included in the count. 
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2.9.6 Determination of Alveolar Macrophage (AM) number 
Alveolar macrophages (AMs) are the most abundant phagocytes and major effectors of innate 
immunity in the alveolar space of the lung. Impaired AM function in smokers is associated with the 
increased risk of pulmonary infections and is implicated in the pathogenesis of chronic obstructive 
pulmonary disease. Quantification of the AMs was done to evaluate if a decrease in the number of 
AMs would affect pulmonary innate immunity. 
 
 Method  
The Hematoxylin and Eosin (H&E) slides were used to quantify the AM number. Alveolar 
macrophage (AM) numbers were determined by using an eyepiece grid (format reticule) of a 
specific surface area (80 µm
2
). All AM (Arrows) inside the specified area (Red angles) were 
counted (see Figure 2.9.6.1). Only cells that are free and where nuclei were clearly seen were 
counted and expressed as number of AM/80 µM
2
. Samples from lungs of at least 5 different 
animals were used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2.9.6: Illustration of the format reticule overlaying a lung tissue sample. Arrows indicate alveolar 
macrophages that lies within the demarcated area of 80 µm
2
 used for counting. 
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For each sample at least 5 fields were counted so that at least 25 fields were counted per lung 
sample. The averages of the 25 fields counted for each lung was used to determine the average AM 
count for that lung. The averages for the lungs of the 5 animals were used to calculate the average 
for each experimental group. AM that touched the upper and left hand lines were considered to be 
within the field and thus counted. Those AM touching the bottom and right hand lines were 
considered to be outside the field and not counted. Fields for counting was randomly selected. 
 
2.10 Statistical Analysis 
One-way ANOVA with Dunnett’s post-test was performed using GraphPad Prism version 5.0 for 
Windows, GraphPad Software, San Diego California USA, www.graphpad.com using the Tukey-
Kramer test, which includes the extension by Kramer to allow for unequal sample sizes. A 
probability level of P<0.05 was chosen as significant to the study and the values were recorded as 
means ± standard error of means. 
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CHAPTER THREE 
Results 
 
3.1 Liquid intake 
Figure 3.1 shows the liquid intake of the mothers during gestation and lactation. From the data, it 
can be deduced that the liquid intake of the control mothers was similar to that of the mothers 
exposed to nicotine, those that received tomato juice only, as well as those that were exposed to 
both nicotine and tomato juice (P>0.05) during gestation (week 1 to 3) and lactation (week 4 to 6). 
 
3.2 Intake of lycopene 
The lycopene intake of the pregnant rats that received tomato juice only, and those that received 
both nicotine and tomato juice was calculated based on the lycopene content of the tomato juice 
(mg/ml) and the volume of the tomato juice consumed by the animals during gestation and 
lactation. The lycopene intake of the pregnant mothers that received tomato juice only during week 
one of gestation (first week of pregnancy) was 20.03±1.34 mg/g body weight/week (mg/wk), and 
22.5±1.77 mg/g/wk (P>0.05) for the pregnant mothers that received a combination of nicotine and 
tomato juice (Table 3.2). At week four (beginning of lactation), the lycopene intake of the mothers 
that received only tomato juice was 10.67±1.4 mg/g body mg/wk, and that of the mothers that 
received a combination of nicotine and tomato juice, this was 10.72±1.02 mg/g/wk (P>0.05).  
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Time (wks) Tomato (T) Nicotine & Tomato (Nic & TJ) P: T vs. N & TJ 
Week 1 20.03±1.34 22.5±1.77 >0.05 
Week 4 10.67±1.4 10.72±1.02 >0.05 
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Figure 3.1: Liquid intake (ml/wk) of the control mothers (water), those that received tomato juice, the nicotine 
exposed (water), and those that received both nicotine and tomato during gestation and lactation. P-value: No 
differences in liquid intake within the control and experimental groups (P>0.05).  
Table 3.2: Lycopene intake per 100 g body weight per week of the rats receiving tomato 
juice only, and the rats receiving both nicotine and tomato juice. 
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3.3 Body weight increase 
Figure 3.3 and Table 3.3 illustrates the weekly increase in body weight of the mothers during 
gestation and lactation when exposed to nicotine, tomato juice supplementation only, or exposure 
of the pregnant mothers to both nicotine and tomato juice. Week three marked the end of gestation. 
Between gestational week one and three, the weekly body weight increase of mothers that were 
exposed to nicotine only, increased by 54 g/wk so that at gestational week three it was at 
354.50±8.31 g, 32.10% higher (P<0.002) than that of the control group which was 268.86±11.80 g 
at gestational week three and thus increased by 29.86 g/wk. The body weight increase up to 
gestational week three of the pregnant mothers that received tomato juice only (283.71±17.87 g) 
and those that received a combination of nicotine and tomato juice (267.50±20.30 g) increased at a 
similar rate (P>0.05). Between gestational week one and week three, the body weight increase of 
the control group was not different from that of the pregnant mothers that received tomato juice 
only, or those that were treated with both nicotine and tomato juice (P>0.05). Week six marked the 
end of lactation and the termination of nicotine and/or tomato juice treatment of the mothers. The 
weekly decrease in the BW of the mothers between gestational week four and week six was such 
that by week six, there was no difference between BW of the control group and that of the nicotine 
group or the other experimental groups (P>0.05). 
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Table 3.3: The effects of maternal exposure to nicotine or tomato juice, or of both nicotine and 
tomato juice on the increase body weight per week of the mothers during gestation (weeks 1 to 3) 
and lactation (weeks 3 to 6). P-value: No differences (P>0.05) in BW within the experimental 
groups during gestation and lactation.  
 
 
 
  
Time (wks) Control Tomato Nicotine Nic &TJ C vs. N 
Week 1-3 29.86 g/wk 28 g/wk 54 g/wk 24.33 g/wk P<0.001 
Week 4-6 14.81 g/wk 10.05 g/wk 7.05 g/wk 13.78 g/wk P>0.05 
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Figure 3.3: The effects of maternal exposure to nicotine or tomato juice, or the combination of both nicotine and 
tomato juice on the body weight of mothers during gestation (weeks 1 to 3) and (week 3 to week 6) lactation 
(Weeks 4 to 6). P-value: No differences (P>0.05) in BW within the experimental groups during gestation or 
lactation.  
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3.4 Litter size at birth 
The data in Figure 3.4 shows that the litter size (pups/litter) at birth of the control mothers 
(12.86±0.59) was the same (P>0.05) as that of the mothers exposed to only nicotine (12.57±0.89), 
those that received tomato juice supplementation only (13.43±0.57), and those that were exposed to 
both tomato juice and nicotine (13.14±0.67). 
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Figure 3.4: The effects of maternal exposure to nicotine or tomato juice, or to both nicotine and tomato juice, on 
the litter size at birth. P-value: No differences in litter size within the control and experimental groups (P>0.05).  
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3.5  The effect of maternal exposure to nicotine, tomato juice, and both 
 nicotine and tomato juice on the growth of the F1 offspring. 
3.5.1 Body weight (BW)  
Figure 3.5.1 illustrates the daily body weight increase of the offspring treated during gestation and 
lactation. No significant differences were observed from a) postnatal day 14 through postnatal day 
84 and b) the body weights of the offspring treated during gestation and lactation were the same as 
the control (P>0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.5.1: The effect of maternal nicotine exposure and tomato juice intake during gestation and 
lactation on the on the BW of the F1 offspring between postnatal day 14 and 84. Postnatal day 14-
84; C vs. N: P>0.05. 
Age 
(Days) 
Control (g) Nicotine (g) C vs. N Tomato Juice 
(g) 
C vs. TJ Nicotine & TJ 
(g) 
C vs. N 
& TJ 
14 27.08±0.85 27.85±0.82 P>0.05 27.82±0.94 P>0.05 26.95±0.93 P>0.05 
21 39.79±1.83 44.63±0.99 P>0.05 36.68±0.85 P>0.05 38.56±1.26 P>0.05 
42 132.36±2.36 132.02±2.81 P>0.05 124.53±2.82 P>0.05 133.56±2.95 P>0.05 
84 256.48±7.39 260.85±8.43 P>0.05 266.99±9.60 P>0.05 253.92±7.94 P>0.05 
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Figure 3.5.1: The effect of maternal exposure during gestation and lactation to nicotine, tomato juice, and both 
nicotine and tomato juice on the BW of the F1 offspring at day 14, 21, 42 and 84 postnatal. No differences 
(P>0.05) within experimental groups from postnatal day 14 up to postnatal day 84.  
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3.5.2  Lung volume (Lv)  
The data in Figure 3.5.2 demonstrates that the daily increase in lung volume (Lv) of the rat pups 
was the same between postnatal day 14 and 42. Following postnatal day 42, the daily increase in the 
Lv of the animals treated with nicotine surpassed that of the control animals and the animals treated 
with tomato juice and the combination of nicotine and tomato juice. Thus, at postnatal day 84 the 
daily increase in Lv of the rat pups treated with nicotine (12.83±0.30 g/ml) was approximately 20% 
higher (P<0.001) than that of the control (9.73±0.23 g/ml) rat pups, and the rat pups exposed to 
tomato juice (9.83±0.22 g/ml) and the combination of nicotine and tomato juice (9.83±0.28 g/ml).  
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Figure 3.5.2: The effect of maternal exposure during gestation and lactation to nicotine, tomato juice, and both 
nicotine and tomato juice on the lung volume (Lv) of the F1 offspring. No dissimilarities exist between postnatal 
days 14 to 42 (P>0.001) of the control and experimental groups. P at postnatal day 84; control vs. nicotine: <0.001. 
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3.5.3 Chest circumference (CC) and Crown-rump length (CRL)  
As for the Lv, the chest circumference (CC) (Figure 3.5.3.1) of the animals increased at a similar 
rate (P>0.05) between postnatal days 14 and 42 when comparing the control group to the 
experimental groups of the corresponding ages. Conversely, an increase in chest circumference 
between postnatal days 42 and 84 of the nicotine increased approximately 30% faster (P<0.05) than 
that of the control group as well as the other experimental groups. At postnatal day 84, a significant 
difference (P<0.001) was observed in the CC of the nicotine (170.76±2.77 mm) treated animals in 
comparison to that of the control (142.83±1.77 mm), tomato juice (145.88±1.89 mm), and both 
nicotine and tomato juice (141.98±1.61 mm) treated groups. As with the BW, a trend is observed in 
the crown rump length (CRL) (Figure 3.5.3.2) of the control and experimental animals and no 
significant differences were seen (P>0.05) between postnatal days 14 and 84. 
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Figure 3.5.3.1: The effect of maternal exposure during gestation and lactation to nicotine, tomato juice, and 
both nicotine and tomato juice on the chest circumference (CC) of the F1 offspring. No differences (P>0.05) 
were observed between postnatal days 14 and 42 of the control and experimental groups. P between postnatal 
day 42 and 84; control vs. nicotine: <0.05. Marked increase in CC at postnatal day 84 (P<0.001). 
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Table 3.5.3.1: The effect of maternal nicotine exposure and tomato juice intake during gestation 
and lactation on the CRL of the F1 offspring between postnatal day 14 and 84. Postnatal day 14-84; 
C vs. N: P>0.05. 
  
Age 
(Days) 
Control 
(mm) 
Nicotine 
(mm) 
C vs. N Tomato 
Juice (mm) 
C vs. TJ Nicotine & 
TJ (mm) 
C vs. N 
& TJ 
14 76.11±1.13 76.38±1.23 P>0.05 79.00±1.82 P>0.05 77.13±1.54 P>0.05 
21 93.71±1.96 98.81±1.03 P>0.05 94.52±1.01 P>0.05 97.14±1.34 P>0.05 
42 147.10±1.19 149.26±1.16 P>0.05 151.29±1.47 P>0.05 150.95±1.48 P>0.05 
84 198.37±1.06 198.16±1.29 P>0.05 198.14±1.55 P>0.05 196.98±1.46 P>0.05 
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Figure 3.5.3.2: The effect of maternal exposure during gestation and lactation to nicotine, tomato juice, and the 
combination of nicotine and tomato juice on the crown rump length (CRL) of the F1 offspring. No differences 
(P>0.05) in the CRL within the experimental and control groups between postnatal days 14 through 84. 
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3.5.4 Chest circumference to body weight (CC/BW) ratio and chest circumference to 
 crown rump length (CC/CRL) ratio 
The chest circumference to body weight ratio (CC/BW) (Figure 3.5.4.1) and the chest 
circumference to crown rump length ratio (CC/CRL) (Figure 3.5.4.2) changed with an increase in 
age for the control and experimental rat pups. Although a trend can be seen in Figure 3.5.4.1, no 
statistical significance (P>0.05) exists between that of the control and experimental animals or the 
respective age groups. Similarly, the CC/CRL ratio show shown in Figure 3.5.4.2 show no 
differences (P>0.05) between the experimental rat pups and that of the control rat pups from 
postnatal day 14 through 84. This is indicative that growth was proportional for both the CC/BW 
and CC/CRL ratios of the rat pups exposed during gestation and lactation. 
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Figure 3.5.4.1: The effect of maternal exposure during gestation and lactation to nicotine, tomato juice, and 
nicotine together with tomato juice on the CC/BW ratio of the F1 generation.  P between postnatal days 14 and 
84; control vs. nicotine: >0.05. 
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Table 3.5.4.1: The effect of maternal exposure to nicotine and the intake of tomato juice during 
gestation and lactation on the CC/BW ratio of the F1 progeny between postnatal day 14 and 
postnatal day 84. Postnatal day 14-84; C vs. N: P>0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Age 
(Days) 
Control 
(mm/g)  
Nicotine 
(mm/g)  
C vs. N Tomato 
Juice 
(mm/g) 
C vs. TJ Nicotine & 
TJ (mm/g) 
C vs. N 
& TJ 
14 293.18±5.88 280.03±9.65 P>0.05 278.07±6.86 P>0.05 281.66±6.64 P>0.05 
21 217.08±7.66 196.71±3.87 P>0.05 221.56±3.56 P>0.05 229.55±7.48 P>0.05 
42 85.48±1.62 89.75±1.64 P>0.05 86.65±1.63 P>0.05 87.00±1.58 P>0.05 
84 56.86±1.06 57.80±1.32 P>0.05 56.84±1.54 P>0.05 57.40±1.21 P>0.05 
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Figure 3.5.4.2: The effect of maternal exposure during gestation and lactation to nicotine, tomato juice, and both 
nicotine and tomato juice on the CC/CRL ration of the F1 offspring. No variations (P>0.05) in the CC/CRL ratio of 
the control and experimental groups between postnatal days 14 and 84. 
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Table 3.5.4.2: The effect of maternal nicotine exposure and tomato juice intake during gestation 
and lactation on the CC/CRL ratio of the F1 progeny between postnatal day 14 and 84. Postnatal 
day 14-84; C vs. N: P>0.05. 
 
 
3.5.5 Lung volume to body weight (Lv/BW) ratio and chest circumference to lung  volume 
 (CC/Lv) ratio 
The lung volume to body weight ratio (Lv/BW) (Figure 3.5.5.1) of the experimental and control rat 
pups were the same (P>0.05) between postnatal days 14 and 21. Also shown is that between 
postnatal day 21 and 42, no significant differences (P>0.05) were observed between the Lv/BW 
ratios and that the growth of the control animals versus the tomato juice and both nicotine and 
tomato juice experimental groups respectively, were proportional. However, following postnatal 
days 42 through to postnatal day 84, a significant dissimilarity in ratios (P<0.05) is illustrated 
between the control animals and that of the nicotine experimental animals. At postnatal day 84, the 
Lv/BW ratios of the nicotine (5.02±0.13 ml/g) animals were roughly 20% higher (P<0.05) than 
those of the control (3.86±0.10 ml/g), tomato juice (3.82±0.11 ml/g), and both nicotine and tomato 
juice (3.91±0.08 ml/g) groups. This is suggestive of disproportional growth.  The data shown in 
Figure 3.5.5.2 illustrates a trend in the chest circumference to lung volume (CC/Lv) ratio. Growth 
was proportional and no differences (P>0.05) are present between the control, tomato juice and the 
combination of nicotine and tomato juice from postnatal day 14 through to 42. It should be noted 
that at postnatal day 84, the CC/Lv ratio of the nicotine (11.61±0.23 mm/ml) animals were 
significantly lower (P<0.05) as opposed to that of the control (14.94±0.30 mm/ml), tomato juice 
(15.07±0.31 mm/ml), and the combination of nicotine and tomato juice (14.80±0.34 mm/ml) 
groups.  
 
Age 
(Days) 
Control 
(mm/mm)  
Nicotine 
(mm/mm)  
C vs. N Tomato 
Juice 
(mm/mm) 
C vs. TJ Nicotine & 
TJ 
(mm/mm)  
C vs. N 
& TJ 
14 103.30±0.78 101.28±2.68 P>0.05 103.30±0.78 P>0.05 97.55±1.04 P>0.05 
21 89.77±1.69 88.28±1.05 P>0.05 85.46±0.78 P>0.05 88.40±1.09 P>0.05 
42 76.34±1.14 78.64±1.01 P>0.05 71.61±1.77 P>0.05 75.98±0.71 P>0.05 
84 72.74±0.70 74.97±0.60 P>0.05 75.05±0.70 P>0.05 73.40±0.77 P>0.05 
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Figure 3.5.5.1: The effect of maternal exposure during gestation and lactation to nicotine, tomato juice, and 
nicotine together with tomato juice of the Lv/BW ratio of the F1 offspring. P between postnatal days 14 and 21; 
control vs. experimental groups: >0.05. No variations (P>0.05) between postnatal days 21 and 42 of the control 
and experimental animals. P<0.05 between postnatal days 42 and 84; control vs. nicotine. P at postnatal day 84; 
control vs nicotine: <0.05. 
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Figure 3.5.5.2: The effect of maternal exposure during gestation and lactation to nicotine, tomato juice, and both 
nicotine and tomato juice on the CC/Lv ratio of the F1 generation. No dissimilarities (P>0.05) between postnatal 
days 14 and 42 of the control and experimental animals. P at postnatal day 84; control vs. nicotine: <0.05. 
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3.6 The effect of maternal exposure to nicotine, tomato juice, and both 
 nicotine and tomato juice on the lung morphometry and morphology of 
 the F1 offspring. 
3.6.1 Tissue and Air volumes (Vt and Va)  
Figure 3.6.1.1 clearly illustrates the marked increase (P<0.001) in lung tissue volumes (Vt) of all 
the groups between postnatal days 21 and 84. The lung tissue volumes of the control animals 
increased linearly from 0.73±0.04 ml at postnatal day 21 to 4.03±0.095 ml at postnatal day 84; the 
animals that received tomato juice increased from 0.60± 0.04 ml at postnatal day 21 to 3.72±0.14 
ml at postnatal day 84, while the tissue volumes of those exposed to the combination of nicotine 
and tomato juice increased from 0.58± 0.05 ml at postnatal day 21 to 3.95±0.13 ml at postnatal day 
84 in the same amount of time. Concomitantly, the Vt of the nicotine group increased from 
0.60±0.04 ml to 2.93±0.065 ml between postnatal day 21 and 84 respectively. The Vt of the 
nicotine exposed animals was lower than that of the control, tomato juice and both nicotine and 
tomato juice exposed animals (P<0.05). Interestingly, up to postnatal day 42, which is 3 weeks after 
nicotine withdrawal, the Vt of the nicotine exposed rats resembles that of the control and other 
experimental groups. Therefore, the reduction in Vt is only evident after postnatal day 42. An 
alteration in Vt is related to changes in Va. This indicates that when a decrease in Vt occurs, as 
observed in nicotine exposed animals at postnatal day 84, a simultaneous increase in Va will be 
present in nicotine exposed rats of the same age. Additionally, this data further infers that tomato 
juice consumption by the mother prevented the effect of nicotine on tissue growth in the lungs of 
the offspring. 
The data also shows a distinct increase in the Va between postnatal days 21 and 84 of the control 
and the animals exposed to tomato juice only and the combination of nicotine and tomato juice 
(Figure 3.6.1.2). The detrimental effects of nicotine on the lung parenchyma are demonstrated by 
the low values in the nicotine exposed rats and become more apparent as the animals’ age.  
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Table 3.6.1: The effect of maternal nicotine exposure and tomato juice intake during gestation and 
lactation on the air volume (Va) in the lungs of the F1 offspring. P at postnatal day 84; C vs. N: 
<0.001. No significant differences (P>0.05) C vs. T or C vs. N & TJ for all age groups. 
  
Age 
(Days) 
Control Nicotine C vs. N Tomato 
Juice 
C vs TJ Nicotine & 
TJ 
C vs. N 
& TJ 
21 20.19±0.29 18.77±0.47 P<0.05 22.76±1.13 P>0.05 22.73±0.75 P>0.05 
42 23.69±0.54 17.54±0.89 P<0.01 23.34±0.50 P>0.01 23.06±1.33 P>0.05 
84 27.57±1.05 15.55±0.18 P<0.001 28.17±0.96 P>0.01 26.56±1.37 P>0.05 
Figure 3.6.1.1: The effect of maternal nicotine exposure and tomato juice intake during gestation and lactation 
on the tissue volume (Vt) of the F1 offspring. Vt at postnatal day 84; C vs. N: P<0.05. 
Figure 3.6.1.2: The effect of maternal nicotine exposure and tomato juice during gestation and lactation on the 
air volume (Va) in the lungs of the F1 offspring. P at postnatal day 84; C vs. N: <0.05. 
Figure 3.6.1.1: Tissue volume (Vt) Figure 3.6.1.2: Air volume (Va) 
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3.6.2 Mean linear intercept (Lm)  
The findings shown in Figure 3.6.2 illustrate that at postnatal day 21, the Mean Linear Intercept 
(Lm) of the control animals were similar to that of the experimental animals of the same age 
(P>0.05). Conversely, between following postnatal day 21 up to postnatal day 84, the Lm of the 
nicotine exposed animals increased significantly so that at postnatal day 84 it was 30% higher 
(P<0.001) in comparison to the control animals of the same age. Between postnatal days 21 and 84, 
the Lm of the control animals decreased from 35.14±0.73 µm to 33.31±1.40 µm, the tomato juice 
exposed animals values decreased from 35.23±1.63 µm to 32.35±1.50 µm, and the Lm of the group 
exposed to the combination of nicotine and tomato juice decreased from 38.90±1.47 µm to 
33.99±0.65 µm (P<0.05). In contrast, the Lm of the nicotine exposed rats increased by 23% from 
36.87±0.75 µm to 48.07±1.88 µm (P<0.001) between postnatal days 21 and 84. No differences 
(P>0.05) were observed between the control animals and those exposed to tomato juice and both 
nicotine and tomato juice of the same age. 
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Figure 3.6.2: The effect of maternal nicotine exposure and tomato juice during gestation and lactation on the 
Mean Linear intercept (Lm) in the lungs of the F1 offspring. Lm between postnatal day 21 and 84; C vs. N: 
P<0.001). 
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3.6.3 Interalveolar septal thickness (Tsept)  
Up to postnatal day 42 Tsept (Figure 3.6.3) of the control rats was similar to that of the rats in the 
experimental groups (P>0.05). The increase in the Tsept of the nicotine exposed animals only 
became evident between postnatal day 42 and 84.The increase was such that at postnatal day 84, the 
alveolar wall thickness of the nicotine exposed animals (13.76±0.92 µm) animals was 34 % higher 
(P<0.001) than that of the control animals (9.04±0.67 µm). Furthermore, at postnatal day 84 the 
Tsept of the controls was the same (P>0.05) as those that received tomato juice only (9.24±0.56 
µm), and those exposed to both nicotine and tomato (8.52±0.28 µm) juice.  
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Figure 3.6.3: The effect of maternal exposure to nicotine, tomato juice, and the combination of nicotine and 
tomato juice during gestation and lactation on the Interalveolar septal thickness (Tsept) in the lungs of the F1 
offspring. Postnatal days 21 to 42; no differences (P>0.05) between control and experimental groups. P at 
postnatal day 84, C vs N: <0.001. 
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3.6.4 Static lung compliance (CSt)  
Figure 3.6.4 illustrates an increase in static lung compliance (CSt) as a result of 1) aging 2) maternal 
exposure to nicotine during gestation and lactation. No significant differences (P>0.001) were 
observed between the control, tomato juice only, nicotine only, and nicotine together with tomato 
juice between postnatal days 21 and 42. However, a significant increase (P<0.001) was observed 
between postnatal day 42 and 84 in lung compliance in the lungs of the nicotine exposed offspring 
in contrast to that of the control rats. The CSt of the nicotine rats increased from 1.66±0.06 ml/cm 
H20/kg at postnatal day 42 so that at postnatal day 84 it was 17% higher (2.01± 0.05 ml/cm 
H20/kg).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.4: The effect of maternal exposure during gestation and lactation to nicotine, tomato juice, and the 
combination of nicotine and tomato juice on the Cst of the F1 offspring. No variations (P>0.001) within the 
control and experimental rat pups between postnatal days 14 and 42. P at day 84; control vs. nicotine: <0.001. 
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3.7 The effect of maternal exposure to nicotine, tomato juice, and both 
 nicotine and tomato juice on the cellularity in the lungs of the F1 
 offspring. 
3.7.1. Lung structure 
Figure 3.7.1 illustrates lung structure of control rats as well as that of rats that were exposed to 
nicotine, tomato juice, or to both nicotine and tomato juice. The administration of nicotine as well 
as the treatment of tomato juice or the combined use of nicotine and tomato juice to the offspring 
was only via the placenta and the mother’s milk. Only the mothers received nicotine or tomato juice 
or both nicotine and tomato juice. From Figure 3.7.1 it is clear that the lung structure of those rats 
that were exposed to nicotine during gestation and lactation display breakdown of alveolar walls 
which result in enlarged alveolar spaces that resembles microscopic emphysema (EM). The site of 
action in the alveolar walls and mechanism of action of nicotine will be investigated and data below 
illustrates the data generated in the study by investigating the cellular characteristics of the alveolar 
wall and alveoli. 
          
          
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.7.1: The effect of maternal exposure to nicotine, tomato juice and a combination of nicotine and tomato juice 
on lung parenchyma of the 84-day-old offspring. A. = Control; B= Nicotine; C. = Tomato juice; D. = Nicotine + 
tomato juice. EM = Emphysema-like lesion.  (Bar = 0.5µm) 
EM 
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3.7.2 Cellular senescence in the alveolar wall 
Figure 3.7.2 shows the effect of maternal exposure during gestation and lactation to nicotine, the 
supplementation of the mother’s diet with tomato juice and the combination of nicotine and tomato 
juice supplementation on the senescent cell number per 100µm of alveolar wall in the lungs of the 
F1 offspring at postnatal day 84. The number of senescent cells per 100 µm alveolar wall in the 
animals that were exposed to nicotine (1.16±0.07 cells/100 µm) was 41% higher (P<0.01) than that 
of the control animals (0.69±0.69 cells/100 µm). The animals exposed to tomato juice (0.73±0.03 
cells/100 µm) and the combination of nicotine and tomato juice (0.78±0.04 cells/100 µm) had a 
comparable senescent cell number per 100 µm length of alveolar wall to that of the control group 
(P>0.05).  
  
Figure 3.7.2: The effect of maternal exposure of the F1 offspring during gestation and lactation to nicotine, 
tomato juice and nicotine together with tomato juice of the on the number of senescent cells per 100µm of the 
alveolar wall at postnatal day 84. No differences (P>0.05) were observed between the control, tomato juice and 
combination of nicotine and tomato juice. Control vs. nicotine: P<0.05. 
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3.7.3 Cellular proliferation in the alveolar wall 
The data in Figure 3.2.3 shows the number of proliferating cells per 100µm alveolar wall length in 
the control animals (1.43±0.06 cells/100 µm) was 21% higher (P<0.001) than the number of 
proliferating cells in the group exposed solely to nicotine (1.12±0.03 cells/100 µm). The amount of 
proliferating cells in the group who received tomato juice (1.50±0.06 cells/100 µm) only and the 
offspring of the mothers who were exposed to both nicotine and tomato juice (1.34±0.04 cells/100 
µm) was the same (P>0.05) to that of the control rats.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 3.7.3: The effect of maternal exposure of the F1 offspring during gestation and lactation to nicotine, 
tomato juice, and nicotine together with tomato juice on the number of proliferating cells per 100µm of the 
alveolar wall at postnatal day 84. Control vs. nicotine: P<0.001. Similarities (P>0.05) existed between the 
control, tomato juice and the combination of nicotine and tomato juice. 
Control Tomato Nicotine Nic+TJ
0.00
0.50
1.00
1.50
2.00
2.50
P
ro
li
fe
ra
ti
n
g
 c
e
ll
s/
1
0
0

m
P<0.001
P>0.05
 
 
 
 
87 
 
Control Tomato Nicotine Nic + TJ
0.00
1.00
2.00
3.00
P
/S
 R
a
ti
o
P>0.05
P<0.001
3.7.4 Cellular proliferation to Cellular senescence (P/S) ratio 
Figure 3.7.4 shows that the P/S ratio of the control (2.07±0.12) animal lungs was significantly 
higher (P< 0.001) in comparison to the rats that were exposed to nicotine (0.97±0.10) only. 
Furthermore no differences (P>0.05) were observed between the P/S ratio of the control 
(2.07±0.12)  rats when compared to the animals exposed to tomato juice (2.05±0.09) only nor those 
who were exposed to both nicotine and tomato juice (1.72±0.08).  
  
Figure 3.7.4: The effect of maternal exposure of the F1 off spring during gestation and lactation to nicotine, tomato 
juice, and nicotine together with tomato juice on the P/S ratio at postnatal day 84. Control vs. nicotine: P<0.001. No 
differences between the control, tomato juice and the combination of nicotine and tomato juice (P>0.05). 
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3.7.5 Alveolar fibroblasts 
The data shown in figure 3.7.5 illustrates the fibroblast count (cells/100 µm) of the alveolar wall 
together with lesions resulting from exposure to nicotine and those exposed to nicotine with no 
emphysematous (NE) lesions. At postnatal day 84, whilst in direct comparison with the control 
animals, approximately a 50% (P<0.001) reduction in alveolar fibroblast number was observed 
between the control (15.94±1.07 cells/100 µm) animals and nicotine (7.05±0.62 cells/100 µm) 
animals with emphysematous lesions.  Concomitantly, a marked decrease (P<0.001) was observed 
between the control (15.94±1.07 cells/100 µm) group and that of the nicotine (9.98±0.54 cells/100 
µm) exposed group without any emphysematous lesions (NE). Similarly when comparing the 
nicotine (9.98±0.54 cells/100 µm) animals with no emphysematous lesions to the nicotine 
(7.05±0.62 cells/100 µm) animals with emphysematous lesions, a significant variation (P<0.05) 
between the respective groups was evident.  
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Figure 3.7.5: The effect of maternal nicotine exposure during gestation and lactation on the alveolar fibroblast number 
of the F1 offspring at postnatal day 84. Arrows= Fibroblasts; NE= Areas in the lung of the animals exposed to nicotine 
where no emphysema is evident. P at postnatal day 84; C vs. N (E): <0.001. Control vs. NE: P<0.001. NE vs. E: 
P<0.05. 
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Figure 3.7.6.1: The effect of maternal nicotine exposure during gestation and lactation on the alveolar macrophage 
(AM) number in the lungs of the F1 offspring. C vs. N: P>0.05. 
3.7.6 Alveolar Macrophage (AM) Number 
Shown in Figure 3.7.6 are the alveolar macrophage counts (cells/80 µm
2
±SEM) in the alveoli at 
postnatal day 84. Although a trend is observed, no significant differences (P>0.05) was observed in 
the AM count between the control (0.20±0.02 cells/80 µm
2
) and the nicotine (0.26±0.20 cells/80 
µm
2
) groups.  
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Figure 3.7.6.2: H & E stain of A) Control and B) nicotine exposed lung of 84 day old rats. Numerous free cells 
(Blue arrows) occur in the alveolus of the lungs that were exposed to nicotine via the placenta and mother’s milk. 
(Bar = 2 µm) 
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3.7.7 Type II alveolar epithelial (ATII) cell number 
The quantification of the number of Type II alveolar cells in the alveolar wall (Figure 3.7.7.1) 
showed that the number of Type II cells in the lungs of the control animals (0.38±0.02 cells/100 
µm) was significantly (P<0.001) lower than that of the nicotine exposed lungs (0.57±0.03 cells/100 
µm). This confirms the morphological observation in Figure 3.7.7.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.7.7.1: The effect of maternal nicotine exposure during gestation and lactation on the number of alveolar 
Type II cells in the lungs of the F1 offspring. P at postnatal day 84; C vs. N: <0.001. 
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Figure 3.7.7.2: Type 2 alveolar epithelial cells (Blue arrows) in the lungs of control (A) and nicotine exposed (B) 
84-day-old rats. Alveolar macrophages (Red arrows). The density of the T2 cells in the lungs of the nicotine 
exposed animals appears to be higher than in control rats. (Bar = 2 µm) 
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3.7.8 Type I alveolar epithelial cell integrity   
A 
B C 
EM 
EM 
Figure 3.7.8: Alveolar wall of a day-84-old nicotine exposed lung (A) with emphysema-like lesions (EM).  All cells are 
in close contact with adjacent epithelial cells and the basement membrane. B) Alveolar wall of 84-day-old control lung 
showing an alveolar wall with intact cells whereas in the alveolar wall of the nicotine exposed rats (C) shows denudation 
(Black arrows) and exposure of the underlying connective tissue (Blue arrows). Cell tight junctions and linking to the 
basement membranes is compromised due to cells sloughing off. C) Block indicated where alveolar wall seen in C is 
taken from. (D) No EM lesions occur in the control lung. 
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3.7.9 Apoptotic cells 
Figure 3.7.9.1 illustrates the number of apoptotic cells per 100 µm of the alveolar wall in the 
nicotine exposed, postnatal day 84 offspring. The number of apoptotic cells observed in the nicotine 
exposed offspring (0.29±0.05 cells/100 µm) was not significantly higher (P>0.05) than that of the 
control animals (0.21±0.02 cells/100 µm). This is evident from the micrograph in Figure 3.7.9.2 
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Figure 3.7.9.1: The effect of maternal nicotine exposure on the number of apoptotic cells in the alveolar walls of 
the F1 offspring at postnatal day 84. C vs. N: P>0.05. 
A B 
Figure 3.7.9.2: Apoptotic cells (Arrows) in the alveolar wall of 84-day-old control (A) and nicotine exposed (B) 
rats. Red arrow indicates an alveolar macrophage undergoing apoptosis. (Bar = 2 µm) 
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CHAPTER FOUR 
Discussion 
4.1 Introduction 
Epidemiological studies have shown that cigarette smoking is the foremost cause of COPD such as 
emphysema and chronic bronchitis and is one of the leading causes of death worldwide (W.H.O., 
2011, Zwerschke et al., 2003). Maternal smoking during pregnancy and lactation accounts for a 
significant percentage of fetal morbidity and mortality (Hammoud et al., 2005). Despite all the 
supporting evidence that maternal smoking is harmful to the unborn child (Schwartz et al., 1972), 
studies show that around 21% of all pregnant women in South Africa smoke during pregnancy 
(Steyn et al., 1997) and 17% of pregnant smokers were found to be in the Western Cape region 
(Chopra et al., 2007). As a result, a staggering 20 to 30% of all newborns exposed to tobacco smoke 
components either before or after birth, increases their susceptibility to respiratory diseases 
(Hofhuis et al., 2003a). Additionally, intrauterine exposure to tobacco smoke is the primary cause 
for a number of unpleasant outcomes including intrauterine growth retardation (IUGR), 
spontaneous abortion, sudden infant death syndrome (SIDS), preterm delivery and low birth weight 
(LBW) (Lieberman et al., 1994, Stocks and Sonnappa, 2013). Studies continue to show that 
nicotine on its own is harmful not only to the fetal lung, but other organs a well, including heart and 
nervous system (Argentin and Cicchetti, 2004, Kleinsasser et al., 2005). Numerous studies have 
indicated that diminished lung function owing to maternal exposure to tobacco smoke is prevalent 
in the offspring of smoking mothers. Consequently, the effects of maternal smoking during 
gestation and lactation on the offspring may even persist into later stages in life (Cunningham et al., 
1994).  
Nicotine is the chief psychoactive component found in tobacco smoke and owing to its addictive 
nature, results in the relapse of many of those who attempt to quit the habit. Nicotine readily 
crosses the placenta and interacts with the nicotinic receptors in the lungs of the developing fetus 
(Sekhon et al., 1999). Page-Sharp et al. (2003) have demonstrated that nicotine has been found to 
occur in considerable amounts in the milk of smoking mothers and more importantly, the 
concentration found in the human mothers’ milk is 2 to 3 times higher than that of the plasma (Luck 
and Nau, 1984b, Dahlstrom et al., 1990). This leads to the interference of normal fetal lung 
development (Maritz et al., 1993). Additionally, nicotine and cotinine has been shown to be present 
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in the urine of 10 month-old non-suckling infants (Rylander et al., 1995) which suggests a passive 
uptake of nicotine. The uptake of nicotine in the present study was passive given that the offspring 
had received nicotine only via the placenta and mothers’ milk.  
 
4.2  Motivation for the use of 1 mg of nicotine/kg body weight/day  
A regular pack of cigarettes contains 8 to 20 mg of nicotine and from that only 1 mg is absorbed 
when smoked. This means that from every cigarette stub containing approximately 1.2 mg of 
nicotine, around 0.1 mg of nicotine will be absorbed by the smoker. Human males and females who 
smoke have a daily nicotine intake ranging between 10.5 and 78.6mg (Kurtoglu et al., 2007). 
Assuming that 90% of nicotine is absorbed via inhalation (Duan et al., 1991), the nicotine intake of 
a 60kg female will vary between 0.16 and 1.18mg nicotine/kg body weight/day. Studies done by 
Benowitz et al. (1982) and Murrin et al. (1987) respectively demonstrated that when pregnant rats 
are treated with 1.5 mg of nicotine per day, the maternal plasma nicotine concentration is similar to 
the values observed in human smokers. In the present study 1 mg nicotine/kg pre-pregnancy 
weight/day was used and was thus within the scope of the nicotine intake of routine smokers. Since 
nicotine readily transcends the placenta and occurs in the milk of both the human and rat mother 
(Maritz and Harding, 2011a), like in humans, the fetal rats will be exposed to nicotine via the 
placenta and therefore it is conceivable that the nicotine content of the female rats was of the same 
magnitude as it is for humans. This indicates that in all likelihood, both perinatal and postnatal 
exposure to nicotine of the rat pups resembled that of the human offspring. Assuming that rats 
respond to nicotine in the same manner as humans, the data produced in the present study can be 
expected to be similar as the effects of nicotine, inhaled by smokers, on the offspring. It should also 
be noted that pregnancy has several variable effects on drug metabolism; hence the plasma nicotine 
concentration determined subsequent to birth may not mirror the actual concentrations throughout 
different periods of pregnancy, specifically during critical windows of organogenesis. The juvenile 
antioxidant capacity of the fetal rat lung renders it highly susceptible to the effects of nicotine 
exposure via the placenta resulting in radical-mediated cell injury (Ziegler et al., 2014, Yoon et al., 
2006). Owing to the slow metabolism of the developing fetus, the half-life of nicotine will be much 
longer in the lungs of the offspring (Maritz and Harding, 2011b). This suggests that the metabolic 
processes affected by nicotine will be extensive in comparison to that of the adult. 
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4.3 The effect of nicotine, tomato juice only, and of both nicotine and  tomato 
 juice on the body weight and litter size of the pregnant and  lactating 
 mothers. 
Smoking during pregnancy is the main cause of increased prenatal morbidity and mortality 
(Kramer, 1987, Hammoud et al., 2005). The harmful constituents found in cigarette smoke, such as 
nicotine, and a number of other harmful compounds, limit the supply of oxygen and vital nutrients 
via the placenta. This results in several undesirable outcomes such as spontaneous abortion, preterm 
birth, sudden infant death syndrome (SIDS), intrauterine growth retardation (IUGR) and as a 
consequence, low birth weight (Lieberman et al., 1994, Salihu and Wilson, 2007, Gluckman et al., 
2008). Studies indicate that a positive correlation exists between low birth weight and fetal onset of 
adult disease including coronary heart disease, type 2 diabetes, and adiposity (Siu and Tyndale, 
2007). As a result, smoking mothers have been strongly encouraged to quit the habit. Several 
pharmacotherapies such as nicotine replacement therapy (NRT) have been advised by health 
professionals to treat nicotine dependence. Although claims exist that NRT is harmless (Zwar et al., 
2006), numerous studies have demonstrated that insistent use of nicotine promotes lung 
carcinogenesis unimpeded by other associated tobacco alkaloids (Dasgupta and Chellappan, 2006, 
Ruiz, 2006). Furthermore, it is not desirable to use nicotine in any form as it crosses the placenta 
and accumulates in the developing fetus (Maritz, 2009). 
It has been suggested that IUGR is a consequence of restricted placental blood flow and thus 
nutrient supply to the developing fetus (Abrams et al., 2000). If so, smoking or NRT will result in 
IUGR and low birth weight: it is therefore conceivable that the litter sizes of the nicotine offspring 
will be smaller than the control animals. However, in this study the number of rat pups per litter 
was the same for the control and experimental groups. Furthermore, as demonstrated in the present 
study, maternal nicotine exposure had no effect on the body weight of the offspring. This implies 
that blood and thus nutrient and oxygen supply to the growing fetuses was sufficient and met the 
demands of the growing fetuses. 
Maternal weight gain during pregnancy is a cardinal indicator of both maternal and infant health 
(Abrams et al., 2000) and deficient gestational weight gain may result in short, mid, or long term 
implications on maternal and pediatric health (Strauss and Dietz, 1999, DeVader et al., 2007, 
Langford et al., 2011). Gestational weight that is well within the recommended range plays a 
crucial role in reducing adverse outcomes such as preterm birth, low birth weight, and IUGR 
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(DeVader et al., 2007, Frederick et al., 2008, Langford et al., 2011). Contrary to this, excessive 
gestational weight gain has been associated with several complications including fetal macrosomia, 
hypertensive syndromes during pregnancy, cesarean section birth, and hemorrhages (Rush, 1974, 
Davies et al., 1976, Rantakallio and Hartikainen-Sorri, 1981).  
The findings in the present study showed that the exposure of pregnant rats to nicotine, tomato 
juice, or the combination of nicotine and tomato juice had no effect on the body weight of the 
pregnant rats during weeks 1 and 2 of gestation. However, the BW of the pregnant rats 
administered with nicotine increased much faster than the control and other experimental groups so 
that at gestational week 3, it was significantly higher. Additionally, the increase in the BW of the 
mother treated with nicotine cannot be due to an increase in amniotic fluid volume. Maternal 
smoking, and therefore by implication, nicotine intake, seem not to affect the amniotic fluid volume 
nor fetal urine output (Burn et al., 1945). Although no evidence exists for the direct effect of this, it 
appears that cigarette smoke and nicotine stimulates the hypothalamus to release antidiuretic 
hormone (ADH) from the posterior lobe of the pituitary gland, causing the inhibition of diuresis 
(Dalessio, 1969) and consequently a shift in favour of an increase in water accumulation in the 
body of the mother. Furthermore, the relationship of nicotine intake and idiopathic edema has also 
been documented (Finch et al., 2004). It is therefore plausible that the continuous exposure to 
nicotine may result in the constant overproduction of ADH and a gradual buildup of water in the 
bodies of the pregnant rats and therefore an increase in BW.  Given that the fluid intake of the 
pregnant rats treated with nicotine was the same as the other groups, it could not have influenced 
the increase in BW. Following birth, the persistent effects of ADH is withdrawn and subsequently 
control of the water balance to normal in the bodies of these animals. This is evident from the fact 
that the BW of the nicotine treated mothers resembled that of the control and other experimental 
groups after birth. Notably, the supplementation of tomato juice in the pregnant rats’ diet averted 
the increase in BW at week three of gestation; however, this mechanism whereby it countered the 
effect of nicotine is not known. Since the litter sizes were unaffected by maternal nicotine intake 
and was thus is not implied in the BW increase of the nicotine treated pregnant mothers. 
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4.4 The effect of maternal exposure to nicotine, tomato juice, and both 
 nicotine and tomato juice on the development of the F1 offspring. 
4.4.1 Body weight (BW) 
Studies have reported that maternal nicotine exposure causes a lower birth weight and body fat of 
the offspring (Grove et al., 2001). This indicates that nicotine exposure during pregnancy may 
result in the interference with the growth of the fetus and offspring leading to intrauterine growth 
retardation (IUGR). Therefore, maternal nicotine exposure during pregnancy is expected to 
suppress fetal growth resulting in lower birth weight of the offspring (Birnbaum et al., 1994, 
Philipp et al., 1984). In the present study, the body weights (BW) of the offspring of mothers who 
were exposed to nicotine during gestation and lactation were not different from that of the control 
animals. This suggests that growth and development were the same for at least up to postnatal day 
84. This suggests that all metabolic and growth control mechanisms were alike. This, in all 
likelihood, explains why maternal exposure to nicotine during gestation and lactation had no effect 
on the body weight of the offspring.  
Contrary to the present study’s findings, Andres and Day (2000) have previously suggested that 
smoking during pregnancy induces intrauterine growth restriction (IUGR). Given that the risk of 
IUGR is significantly greater in females who smoke cigarettes with a higher nicotine content 
(Bainbridge and Smith, 2006),  it is conceivable that nicotine is the causative factor. Furthermore, it 
is plausible that placental perfusion during pregnancy will be compromised by maternal smoking as 
a result of nicotine-induced vasoconstriction  in the placenta (Economides and Braithwaite, 1994). 
However, contrary to this, Bainbridge and Smith (2006) demonstrated that nicotine does not 
influence the feto-placental blood supply. Hence, it is questionable that the nutrient supply to the 
developing fetus will be compromised by nicotine. In support of the latter, studies done by Maritz 
and Windvogel (2003) showed that  the exposure of pregnant rats to nicotine had, like in the present 
study, no effect on the body weight of the offspring. In fact, any contribution  to IUGR in smokers 
is not at the level of the feto-placental perfusion but rather at the level of placental function and/or 
uterine function (Maritz and Windvogel, 2003).  
Moreover, this is well substantiated by the fact that maternal smoking alters critical characteristics 
of placental function including, progesterone production (Piasek et al., 2001); estrogen metabolism 
(Zhu et al., 2002); amino acid transport (Pastrakuljic et al., 1999); and the location and activity of 
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drug metabolizing enzymes (Zdravkovic et al., 2005). However, in the present study, and at the 
concentration used, nicotine had no such effect as tobacco smoke in addition to nicotine; also 
contains a variety of other foreign substances. 
On the other hand, Philipp and co-workers (1984) and Birnbaum et al. (1994) demonstrated that 
with the use of relatively high concentrations of nicotine, namely 3 and 6 mg nicotine/kg body 
weight/day respectively, causes vasoconstriction in the placenta and may result in a decrease of the 
nutrient supply to the fetus. Consequently this will result in a lower birth weight of the offspring. 
This is unlike the effect of 1 mg nicotine/kg BW/day. This suggests that uterine vasoconstriction 
occurs at higher nicotine concentrations with a consequent lower BW at birth. In the present study, 
maternal exposure to nicotine during gestation and lactation had no effect on the body weight of the 
offspring.  
As shown by Benowitz et al. (1982) that when pregnant rats received 1.5mg nicotine/kg body 
weight/day, the plasma nicotine concentration values were similar to that of human smokers. It is 
possible that perhaps the treatment of 6 and 3mg of nicotine/kg body weight/day may have been too 
steep. Benowitz et al. (1982) and Murrin et al (1987) established that the birth weight of the 
offspring, litter size, and postnatal weight gain was unaffected. Thus, the present study is consistent 
with the findings of Benowitz et al (1982) and Murrin et al (1987), as the nicotine dosage used in 
the present study was in accordance with that consumed by human smokers and thus had no effect 
on the body weight of the offspring. Given that nicotine was only dispensed once per day, it is 
possible that the amount of time placental vasoconstriction lasted might not have been long enough 
to cause a decrease in nutrient supply, and therefore no significant influence on the growth of the 
fetus. On the other hand, nicotine accumulates in the fetus due to a slow degradation thereof by the 
fetal tissue (Maritz and Harding, 2011b) and it is therefore conceivable that it will still impact on 
the development of the fetus despite a short period of placental vasoconstriction and subsequently 
nutrient supply for that period of time. 
These results stand agreement with previous studies in which it was also showed that maternal 
nicotine exposure did not affect growth parameters such as chest circumference, crown-rump 
length, and body weight of the offspring (Maritz et al., 2011b, Maritz and Windvogel, 2003, 
Pausová et al., 2003).  
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Studies done by Fowden and colleagues (2006) revealed that the duration, severity, and type of 
insult can affect intrauterine growth. This supports the study done by Philipp et al. (1984) and 
Birnbaum et al. (1994) namely that by increasing the nicotine intake will result in low birth weight 
of the offspring due to the high nicotine concentrations.  However, as shown by the present study, 
although proportional growth in the offspring was not affected by maternal nicotine exposure 
during gestation and lactation, it does not suggest that maternal nicotine had no effect at a cellular 
level and on the homeostatic mechanisms of the offspring.  
The present study also established that the CC/CRL ratios as well as the CC/BW ratios were 
unaffected by the maternal exposure to nicotine during pregnancy and lactation. This implies that 
nicotine had no effect on the proportional growth of the offspring. It is interesting that the CC, 
which is an indicator of lung volume (Borkan et al., 1981), of the nicotine exposed rats were 
increased at day 84 which suggest that the lung volume in the nicotine exposed offspring was 
increased as well. 
 
4.4.2 Lung volume (Lv) 
Despite the fact that the BW and growth parameters of the offspring was unaffected by maternal 
nicotine exposure during gestation and lactation, the lung volumes (Lv) of the 84-day-old animals 
that were exposed to nicotine were indeed higher than the control and the other experimental 
groups. This increase in lung volume was evident after postnatal day 42 and gradually became more 
significant as it reached postnatal day 84. Approximately a 20% increase in Lv was observed at 
postnatal day 84. Gehr et al. (1981) showed that bigger animals require a larger internal surface 
area in the lungs to adequately supply oxygen to meet the higher demand for oxygen by the larger 
body. The increase in CC and lung volume at postnatal day 84 was not a response to an increased 
demand for oxygen due to an increase in BW because the BW was not different from that of the 
controls of the same age. The larger lung volumes were in all likelihood due to a gradual 
deterioration of the connective tissue framework of the lung later in the life of the offspring. The 
gradual increase in lung volume later in the life of the nicotine exposed rats can possibly be the 
reason for the gradual increase of the chest circumference of these animals as seen in emphysema 
(Stanley J. and Swierzewski, III, MD., 2000). A gradual deterioration of the connective tissue 
framework may result in an increase in the compliance of the lungs of the offspring that were 
exposed to nicotine via the placenta and mothers’ milk. 
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The present study also demonstrated that between postnatal days 14 through 42 the Lv/BW ratios of 
the control and experimental animals were the same. However, following postnatal day 42 through 
84 the Lv/BW ratios of the nicotine exposed offspring were higher than that of the control animals. 
The increase in Lv/BW ratios of the postnatal 42 and 84 day old rats exposed to nicotine is a clear 
indication of the disproportionate increase in lung volume of these animals. However, even though 
the CC of the 84-day-old nicotine exposed rats was higher than that of the control rats of the same 
age, it is unlikely that the difference in CC/Lv can be attributed to disproportional growth, but 
rather to a change in the compliance of the lungs of these animals. The supplementation of tomato 
juice in the mother’s diet prevented the faster increase in Lv of the lungs of the nicotine exposed 
rats. The increase in Lv of the nicotine exposed rats was more evident as they aged suggesting that 
it was programmed during the fetal and early neonatal stages to increase faster later in life.  
 
4.5 The effect of maternal exposure to nicotine and tomato juice on lung 
 morphometry and morphology of the F1 offspring 
4.5.1 Lung structure 
In the present study, nicotine administration to the F0 generation commenced 24 hours after mating. 
The F1 generation therefore only received nicotine via the placenta and mothers’ milk. Nicotine 
exposure occurred during all phases of lung development in utero, that is during the phases of rapid 
alveolarisation (postnatal days 4-13) (Windvogel, 2006a), the phase of equilibrated lung growth 
(postnatal days 14-21) (Schittny and Burri, 2008), and terminated at weaning which is postnatal day 
21. During rapid alveolarisation, the number of alveoli increases with a concomitant decrease in the 
size of the alveoli. This means that the tissue volume (Vt) of the lung will increase as it matures and 
air volume (Va) is not equated to lung volume (LV). The Vt calculated in this study demonstrated 
that the lungs of all the groups in fact did increase between postnatal days 21 and 84. However, 
between postnatal days 42 and 84, the Vt of the nicotine exposed animals was considerably lower 
than that of the control animals. Typically, when a decrease in Vt occurs, a concomitant increase in 
Va will be observed; the late onset of the decline in tissue density with a simultaneous decrease in 
Va is an indication that the lungs of these animals were programmed to deteriorate later in life. This 
is also an indication of an increased susceptibility to stress damage later in the life of these animals. 
In contrast to the control, tomato juice only and both nicotine and tomato juice; the alveoli observed 
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in the nicotine exposed progeny appeared to be larger in size but fewer in number. This marked 
reduction in Vt seen in the nicotine exposed rats can be ascribed to a gradual destruction of the 
alveoli and the formations of emphysema-like lesions.  
The breakdown of the alveolar walls and the increase in static compliance suggests that the 
connective tissue framework was compromised later in the life of the rats that were exposed to 
nicotine via the placenta and mother’s milk. Hence, it follows that the alveolar volume of the 
nicotine exposed animals will be greater in comparison to the control rats. This is supported by the 
higher Mean Linear Intercept (Lm) of the nicotine exposed progeny. It should especially be noted 
that the decrease in Vt accompanied by an increase in Lm only became evident after postnatal day 
42 which suggests that the lungs of the nicotine exposed offspring was programmed to start 
deteriorating later in the life of the offspring. This suggests that up to postnatal 42, the tissue 
volume as well as the alveolar volume and number in the lungs of the F1 progeny was not 
significantly affected by nicotine exposure during gestation and lactation.  
Additionally, the destruction of alveoli is shown by the Lm which in fact gradually increased 
following postnatal day 21. This means that even though the difference in Vt only became apparent 
after postnatal day 42, the diameter of the alveoli had already increased and thus showing early 
onset of microscopic emphysema (Collins et al., 1985, Elliot et al., 2001). Light micrographs have 
indeed demonstrated emphysema-like lesions in the lungs of the nicotine exposed rats following 
postnatal day 42. Furthermore, one should note that tomato juice intake by the mother inhibited the 
effect of nicotine on Vt in the lungs of the offspring. 
Since the Vt of the nicotine exposed offspring gradually decreased after postnatal day 42, a thinning 
of the alveolar wall was expected to ultimately give rise to alveolar wall destruction observed 
during parenchymal damage. Maritz and Windvogel (2005) indeed showed that at postnatal day 21, 
the alveolar walls or interalveolar septal thickness (Tsept) of the nicotine exposed animals were 
thinner than the control animals of the same age. However, contrary to these findings, in the current 
study an increase in Tsept of the postnatal day 84 nicotine exposed rats was observed and can be 
ascribed to an imbalance in the synthesis and degradation of the alveolar wall components.  Since 
the thickening of the alveolar wall became apparent only later in the life of the nicotine exposed 
offspring, it is plausible that the homeostasis of the metabolic processes that are geared to maintain 
the integrity of the alveolar wall was compromised. 
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Since the Vt of the nicotine exposed animals decreased despite the increase in Tsept, it is likely due 
to faster deterioration of the lung parenchyma, and thus Vt. Since the offspring only received 
nicotine via the placental blood and mothers’ milk, these changes are unlikely as a result of the 
direct effect of nicotine or its metabolites. This is verified by the fact that the half-life of nicotine is 
around 90 minutes (Benowitz et al., 1982) and the primary metabolite, cotinine, is 16 to 19 hours 
(Jarvis et al., 1988). It is also unlikely to be as a result of an oxidant-antioxidant imbalance at this 
relatively late stage of lung growth seeing as these alterations in the alveolar region of the rats’ 
lungs occurred 3 to 9 weeks post nicotine exposure, and all the metabolites were expelled from the 
lungs of the F1 progeny. These changes are rather due to a change in the factors that maintain lung 
integrity as the animals age.  
Since nicotine is genotoxic (Kleinsasser et al., 2005) and has been shown that long-term exposure 
gives rise to an inclination towards genetic instability (Hartwell and Kastan, 1994, Sastry et al., 
1998, Guo et al., 2005a), it is highly likely that maternal nicotine exposure during phases of rapid 
cell proliferation and differentiation may in fact result in changes in the “program” that controls 
lung development, maintenance of lung integrity, and aging of lung tissue which may render the 
lungs more susceptible to disease (Maritz et al., 2011b, Maritz and Windvogel, 2003). The increase 
in the alveolar volume as well as alveolar wall thickening indeed point to the development of 
emphysema-like lesions in the lung parenchyma. These collectively are all signs of premature lung 
aging (Bruin et al., 2008a) and negatively impacts the function of the lung as a gas exchanger. 
 
4.5.2 Tomato juice supplementation 
The present study showed that by supplementing the diets of the pregnant rats with tomato juice 
during gestation and lactation inhibited the unfavourable effects of nicotine on the lungs of the F1 
progeny. Since tomato juice is rich source of lycopene and other antioxidants, it is plausible that the 
daily intake of tomato juice augmented the antioxidant status of the mother as well as the offspring, 
and thereby the capacity to guard itself against exogenous substances such as nicotine. Even though 
lycopene is the primary bioactive component found in fresh tomatoes and tomato products 
(Takeoka et al., 2001), it is possible that other antioxidants and phytonutrients in tomato juice may 
have contributed in protecting the developing fetal lung against the deleterious effects of nicotine.  
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As for the exposure of nicotine, tomato juice supplementation took place during the phases of lung 
development when cell turnover is rapid as well as when the release of oxidants under the influence 
of nicotine (Zhao et al., 2006) was conceivably at its peak. From the present study, it is evident that 
tomato juice, and presumably lycopene and other phytonutrients found in tomato juice, safeguarded 
the lungs during phases of rapid lung growth when it is most sensitive to the adverse effects of 
foreign materials, such as nicotine. Studies done in humans demonstrated that lycopene alone 
prevented DNA damage (Neyestani et al., 2007) as well as cell membrane oxidation in vivo .  It is 
therefore possible that the lycopene in tomato juice improved the protection mechanisms of the 
mother and fetus to such an extent that it resembled the lungs of the control animals. Furthermore, 
based on the data in the current study, and directly extrapolating from rats to humans, a daily intake 
of 250 ml (approximately one and a half glasses) of tomato juice will contain enough lycopene, 
phytonutrients, and other antioxidants such as vitamin C to protect the fetus in a 60 kg human 
female. 
 
4.6 The effects of maternal nicotine exposure on the cellular integrity of the 
 alveolar walls in the lungs of the F1 offspring.  
Morphometric data showed that exposure of the fetus and neonate to nicotine via the placenta and 
mother’s milk interfered with the homeostatic mechanisms that are essential to maintain the 
structural and functional integrity of the lungs of the offspring throughout life. Since these changes 
in the lung parenchyma were only evident later in the life of the nicotine exposed offspring, it was 
suggested that these changes were programmed in utero when the developing organs were most 
sensitive to the effects of the environment. Any changes in the metabolism, such as the disturbance 
of the balance between synthesis and breakdown of components of the  extracellular matrix with the 
consequent thickening of the alveolar walls at postnatal day 84, implies that the cellular 
components of the alveolar wall, such as fibroblasts, were  involved. It was thus important to 
investigate the cell integrity of the alveolar walls, such as fibroblasts, type I and –II cells and even 
the alveolar macrophages that occur free in the alveoli. This will help to establish whether the 
cellular composition of the parenchyma was affected. Any change in the composition will be an 
indication of the site of action of nicotine as well as of the consequences since each cell type plays a 
unique role in maintaining the parenchymal integrity of the lung in the long term. The impact of 
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maternal nicotine exposure on these cells was only investigated at postnatal day 84 since that is 
when most of the changes in lung structural integrity became evident. 
 
4.6.1 Apoptosis and cell proliferation 
Lung development and maintenance necessitates a very dynamic process of cellular replication and 
apoptosis (Aoshiba and Nagai, 2009), especially since the lung is exposed to many exogenous 
substances such as atmospheric pollutants particularly in smokers. Apoptosis, or programmed cell 
death, plays a crucial role in numerous physiological processes during fetal lung development and 
in adult tissue. This means that the relationship between cell death and cell replacement is tightly 
controlled to ensure maintenance of lung structure and function. Although many hypotheses for the 
development of emphysema have been put forward including the proteinase-antiproteinase theory, 
Calabrese and colleagues (2005) have proposed that an apoptosis-proliferation imbalance 
contributes to the development of emphysema. It was indeed shown that apoptosis and cell 
proliferation does not increase at the same rate (Imai et al., 2005). Consequently, this results in a 
loss of cells in the alveolar walls during emphysema (Segura-Valdez et al., 2000) and subsequent 
deterioration of parenchymal tissue. Banerjee et al. (2007) has indeed demonstrated that smoking 
increases apoptosis with a concomitant decrease in cell proliferation which contributes to 
emphysema as a smoker ages. Although it is said that nicotine deregulates essential biological 
processes like apoptosis and angiogenesis (Zeidler et al., 2007), it was evident from the present 
study that nicotine exposure via the placenta and mothers’ milk had no significant effect on the 
apoptosis in alveolar walls of the F1 offspring however, has the tendency to be higher.  It is 
therefore not likely that the destruction of alveolar walls and the consequent increase in alveolar 
volume could solely be ascribed to an apoptosis-cell proliferation imbalance in the lungs of the 
nicotine exposed progeny. 
 
4.6.2 Cellular proliferation and cellular senescence 
Based on the findings of the present study it is apparent that maternal nicotine exposure during 
gestation and lactation reduced the rate of cellular proliferation in the alveolar wall of the F1 
offspring. This was accompanied by an increase in the number of senescent cells in the alveolar 
walls of the nicotine exposed F1 progeny in comparison to that of the control animals. Furthermore, 
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this resulted in a P/S ratio in the lungs of the nicotine exposed offspring that was significantly lower 
than that of the control and other experimental groups. The skewed ratio in the lungs of the nicotine 
exposed animals during gestation and lactation indicates a cell proliferation-cell senescence 
imbalance. The shift in cell proliferation-cell senescence balance in favour of senescence will 
compromise the lungs ability to replace damaged and/or dead cells thus causing a gradual loss of 
alveolar wall integrity. Since the exposure of nicotine via the placenta and mothers’ milk had not 
increased apoptosis in the lungs of the nicotine exposed F1 offspring, it follows that apoptosis did 
not influence the imbalance in cell death and cell replacement in the alveolar walls. However, due 
to accelerated cellular senescence accompanied by a slower cell turnover, it is inevitable that that 
alveolar wall destruction will occur. These findings furthermore suggest that exposure to nicotine 
during gestation and lactation caused the lungs of the F1 offspring to age prematurely.  
The imbalance between cellular damage and repair became evident relatively late in the life of the 
F1 progeny and seems to be irreversible. It is therefore highly likely that maternal exposure during 
gestation and lactation at critical windows of lung development induced developmental 
modifications at a cellular level which contributed to perpetual physiological, structural, and 
epigenetic alterations in the lungs of the F1 offspring resulting in micro emphysema-like lesions 
later in life. As a result of impaired repair mechanisms in the lungs of the nicotine exposed animals, 
it is conceivable that the lungs of the offspring will be deemed more vulnerable to stress induced 
damage such as atmospheric air pollutants. 
The mechanism whereby the exposure of the F1 offspring to nicotine during pregnancy and 
lactation caused an imbalance in the cell proliferation-cell senescence is likely owing to oxidative 
damage stimulated during the early stages of lung growth. By treating the mothers’ with nicotine, it 
reduces the antioxidant capacity of the mother and fetal lung.  Therefore, it increases the oxidant 
load of both mother and fetus (Durak et al., 2002) and thus expose the developing lung to higher 
levels of oxidants. Furthermore, the increase in oxidant load and compromised antioxidant 
capability or low antioxidant levels will thus predispose the rapidly proliferating cells of the lungs 
of the offspring to programming. This is substantiated by the observation that the intake of tomato 
juice by the mothers’ treated with nicotine averted the alterations in the cellular processes involved 
the alveolar walls of the offspring. This may be due to the maintenance of the mothers’ antioxidant 
status and by implication, the offspring, giving rise to an augmented defense against oxidant 
induced programming in the lungs of the F1 offspring. 
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So far the data shows that overall cell proliferation was suppressed. At the same time the senescent 
cell numbers per length of alveolar wall increased. This implies that the accumulation of senescent 
cells will also contribute to fewer cells that can proliferate. The data so far represents an overall 
picture of cell senescence and proliferation of all parenchymal cells. It is important to establish 
what the response of specific individual cells in the alveolar walls to nicotine exposure is in order to 
determine the site of action of nicotine and the consequences on lung structure and function in the 
longer term. Fibroblasts, type I and –II cells density (numbers/length of alveolar wall) of the 
alveolar walls were determined, as well as that of macrophages in the alveoli since there is 
communication between all these cells. 
 
4.6.3 Fibroblast Density  
Cigarette smoke has shown to have cytotoxic effects on lung fibroblasts (Ishii et al., 2001) which 
have led to the induction of apoptosis of these cells (Carnevali et al., 2003, Baglole et al., 2006). 
Pulmonary fibroblasts are the primary cell type responsible for synthesis and secretion of the main 
components of the alveolar ECM (Koh et al., 1996) which plays a major role in the connective 
tissue framework of the lung. Moreover, pulmonary fibroblasts have been said to participate in 
alveolar growth and multiplication (Warburton and Bellusci, 2004). 
As shown in this study, the fibroblast density was markedly reduced in the alveolar walls of the 
lungs of the 84-day-old F1 offspring exposed to nicotine in utero and during lactation in 
comparison to that of the control animals. It is also interesting to note that while a significant 
decrease in the fibroblast density was seen between the control animals and the nicotine exposed 
offspring, the fibroblast density in areas where emphysematous-like lesions were present, was 
significantly lower than in the areas where no emphysematous-like lesions were observed. This 
implies that the lower fibroblast density is associated with emphysema-like lesions. It is plausible 
that the fibroblasts are sensitive to the effect of nicotine and develop premature senescence and 
become unable to proliferate as the lungs grows and develop. Since alveolar fibroblasts secrete 
growth factors that target both alveolar epithelial and endothelial cells (Plantier et al., 2007) one 
would anticipate that due to injury, the fibroblast activity would be increased in areas where 
alveolar damage has occurred. Nobukuni et al. (2002) demonstrated that cigarette smoke inhibits 
pulmonary fibroblast proliferation and migration. The data in the current study indicate that 
nicotine in tobacco smoke contributes to the suppressed fibroblast proliferation in the lungs of 
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smokers. It is therefore conceivable that this may be the reason as to why the fibroblast density was: 
1) distinctly reduced in the lungs of the nicotine exposed F1 offspring, and 2) a further reduction of 
fibroblasts in areas with emphysematous-like lesions. Moreover, as for the effect of maternal 
nicotine exposure on other cell types, chronic exposure to cigarette smoke results in a senescent 
fibroblast phenotype (Nyunoya et al., 2006). This implies that maternal nicotine exposure during 
gestation and lactation probably induces a decrease in the number of metabolically active 
fibroblasts available for alveolar multiplication and growth via premature origins of these cells. 
This is especially evident later in the life of the nicotine exposed offspring and exacerbated in 
regions where emphysema-like lesions has developed. Due to financial constraints, we were unable 
to demonstrate whether the supplementation of tomato juice in the diet of the mothers’ treated with 
nicotine would avert the deleterious effects on pulmonary fibroblasts. However, if directly 
extrapolated from previous results shown in the present study, we can safely assume that the 
supplementation of tomato juice in the mothers’ diet may have prevented the reduction in fibroblast 
activity, but this would require further study. 
 
4.6.4 Alveolar macrophages (AM) 
The findings in the present study show that maternal nicotine exposure during gestation and 
lactation had no effect on the alveolar macrophage (AM) number in the lungs of the nicotine 
exposed offspring at postnatal day 84. AM occurs free in the alveoli and plays a fundamental role in 
the protection of lung integrity. Although the number in AM were unaffected, it is likely that the 
metabolic activity of the AM were affected. In support of this are studies done by Wongtrakool and 
co-workers (2012) that  demonstrated that nicotine suppresses the innate immune response of these 
cells to foreign particles that enter the alveoli. It is therefore plausible that although the alveolar 
macrophage numbers were not affected by maternal nicotine exposure during gestation and 
lactation, the innate immunity of these lungs might be affected since it is plausible that more 
alveolar macrophages are senescent than in the control lung and thus not effective in protecting the 
lung. This probably explains why in utero nicotine exposure, mediated in part via the alpha-7 
nicotinic acetylcholine receptor (α-7 nAChR), and increases the risk of lower respiratory tract 
infections in neonates due to a lower phagocytic function (Wongtrakool et al., 2012). 
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4.6.5 Alveolar Type I (ATI) and Type II (ATII) cells 
Exposing the fetus to nicotine via the placenta and mother’s blood resulted in enhanced alveolar 
type II (ATII) proliferation in the lungs of the day 84 offspring. These findings are consistent with 
that of Maritz and Thomas (1995). It is however, important to note that the faster type II cell 
proliferation in the latter study took place while the mother was still exposed to nicotine and the 
offspring therefore still receiving it via mother’s milk. In the present study the type II cell 
proliferation was still markedly faster in the 84-day-old nicotine exposed offspring than that of the 
control animals despite the fact that it was not exposed to nicotine since weaning on postnatal day 
21.  This implies that type II cell proliferation remains high in these rats even though there is no 
nicotine present in the lungs at this late stage. It is therefore highly likely that this is a programmed 
process and in all likelihood gave rise to a permanent faster type II proliferation.   
 Whether the rapid Type II proliferation in the alveolar walls of the nicotine exposed offspring can 
be attributed to a direct effect of nicotine during gestation and lactation on the type II cells is not 
known. There are however 2 possible mechanisms that may induce the observed proliferation of 
type II cells in this and other studies. Firstly, Rehan et al. (2007) reported that ATII cell 
proliferation in nicotine exposed animals is a result of the indirect effect of nicotine, that being a 
paracrine mechanism(s) secondary to its effects on adepithelial fibroblasts. Alveolar interstitial 
fibroblasts (AIF’s) have been shown to express the peroxisome proliferator activated receptor 
(PPAR)-γ. The PPAR-γ is reported to have an antimitogenic role in other systems, where it is has 
been shown to impede cell proliferation by regulating the activation of cyclins and cyclin dependent 
kinases (Law et al., 2000). AIF’s that are situated adjacent to ATII cells express PPAR-γ (Rehan et 
al., 2006) and nicotine downregulates PPAR-γ by these fibroblasts (Rehan et al., 2005). 
Furthermore, from the observations that nicotine exposure during gestation and lactation markedly 
reduced the fibroblast activity in the lungs of the F1 offspring, it follows that ATII cell proliferation 
in the nicotine exposed progeny can possibly be ascribed to a) the imbalance of fibroblast-derived 
epithelial cell growth stimulatory and –inhibitory paracrine mediators or b) the reduction in 
fibroblast numbers and therefore an absence in the expression of PPAR-γ resulting in ATII cell 
proliferation.  
Secondly, although the alveolar type I cells were not quantified in the present study; micrographs 
depicted the sloughing of these cells from the alveolar basement membrane in the lungs of the 84-
day-old nicotine exposed offspring. It is known that when type I cells are damaged it is replaced by 
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the type II cells; a process that requires type II cell proliferation and the differentiation of one of the 
daughter cells into a type I cell to replace the damaged type I cell (Crapo et al., 1980). These 2 
suggested mechanisms are indirect and require a type II cell that is responsive to the external 
stimuli, such as type I cell death. 
The cell-cell junctions of the ATI cells were damaged as part of the cells sloughing off the 
basement membrane. The reason for the apparently shorter lifespan of the type I cell is not known. 
It is however, known that the type I cell is dependent on glycolysis for energy and thus survival. It 
is has been shown that maternal nicotine exposure suppress glycolysis irreversibly in the lungs of 
the nicotine exposed animals (Kordom et al., 2003). It is therefore plausible that the shorter lifespan 
of the type I cells are due to a lower energy supply via glycolysis. It was indeed recently shown that 
glycolytic enzymes can modulate the life span of early fibroblasts (Kondoh et al., 2005). An 
increase in glycolysis decreases oxidative damage of these cells and delay onset of senescence 
(Figure 4.6.5.1). Inhibition of glycolysis on the other hand, results in less protection against 
oxidative damage and is associated with the premature onset of senescence. Furthermore, it has 
been demonstrated that glycolytic flux declines during senescence in both murine and human 
fibroblasts (Zwerschke et al., 2003, Kondoh et al., 2005). This means that the inhibition of 
glycolysis could also contribute to premature aging of the type I cells. It is also plausible that the 
inhibition of glycolysis by nicotine in the long term also resulted in premature senescence of 
fibroblasts as well as type I cells and thus the role it plays in the maintenance of lung structural 
integrity and function as the animal ages. This might explain the lower number of fibroblasts in the 
alveolar walls of the nicotine exposed progeny as well as the sloughing from the basement 
membrane of the type I cells. It is therefore tempting to speculate that inhibition of glycolysis may 
induce premature senescence and degeneration of alveolar walls and the subsequent development of 
microscopic emphysema.  
 
 
     
  
     Glycolysis Senescence Oxidative stress 
Figure 4.6.5: Illustrates that glycolysis suppress senescence and protect against oxidative stress. Inhibition of 
glycolysis compromises the role of glycolysis in controlling senescence and oxidant levels in the lung. 
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Apart from glycolysis mitochondria act as a major source of energy that is essential for normal cell 
function. However, perturbation of mitochondrial homeostasis may accelerate senescence (Ziegler 
et al., 2014). In a previous study it was found that exposure to nicotine resulted in mitochondrial 
swelling (Maritz and Thomas, 1994, Maritz and Thomas, 1995). In a study by Ziegler et al. (2015)   
it was shown that the mitochondria of senescent cells are abnormally enlarged. Some studies also 
showed that these mitochondria release more oxidants which may contribute to cellular senescence 
(Yoon et al., 2006). Although no data was generated in the present study regarding mitochondrial 
structure and function, the data generated in studies investigating the effect of maternal nicotine 
exposure on lung cell and mitochondrial integrity suggest that the changes induced in the 
mitochondria in the cells of the alveolar wall may contribute to cell senescence and premature 
aging. On the other hand, in a previous study it was shown that although maternal nicotine exposure 
induces mitochondrial swelling, it had no effect on the oxygen consumption of the lung tissue in 
vitro (Maritz, 1986). It is thus not likely that nicotine induced senescence is promoted via its impact 
on mitochondria. The swelling of the mitochondria appears not to be equal to enlargement of the 
mitochondria in senescent cells. It furthermore also implies that mitochondrial swelling is not a sign 
of cell senescence. 
In addition, in a study by Zwerschke et al. (2003)   it was found that an elevation of the intracellular 
AMP level  occur during replicative senescence, which is sufficient to induce both growth arrest 
and properties of the senescent phenotype. Since maternal nicotine exposure during gestation and 
lactation increased the total AMP in the lungs of the offspring (Maritz and Burger, 1992), it is 
conceivable that this may contribute to premature senescence of the cells in the alveolar walls and 
thereby resulted in a gradual degradation of the alveolar walls over time.  
Apart from being an integral part of the alveolar wall the alveolar epithelial cells also play a crucial 
role in the innate immunity of the lungs (Derscheid and Ackermann, 2013).  Intact cell-cell 
junctions act as a barrier against foreign materials and in this way prevent it from damaging 
underlying cells and from entering the circulation. It also protects the underlying basement 
membrane against the harmful effects of, for example, inhaled oxidants. It is therefore clear that 
damage to these cells, as illustrated in this study, will not only compromise the structural integrity 
of the alveolus, but also its role in innate immunity which will consequently increases the 
vulnerability of the F1 offspring lungs to respiratory diseases.  
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4.6.6 Endothelial cells 
The endothelial cells are also part of the alveolar wall and damage to these cells, or if the processes 
that are responsible for the maintenance of homeostasis of these cells, its role in the maintenance of 
the integrity of the alveolar wall may also contribute to a gradual breakdown of the alveolar wall 
with a concomitant increase in alveolar volume. Although these cells were not studied in this 
project it is plausible that these cells were also affected because the structure and function of the 
endothelial cells on both sides of the blood-air barrier requires fully functional fibroblasts (Borok et 
al., 2011). 
In summary, the results from this study and information from the literature shows that maternal 
nicotine exposure to nicotine during gestation and lactation programmed the lungs of the offspring 
to develop senescence prematurely. A consequence of the premature aging of the lungs is the 
increased susceptibility to disease due to: 
1. Alveolar walls that deteriorate faster due to the imbalance between cell replacement and 
cell death. This is reflected in slower cell proliferation, type I cell damage, and 
decreased fibroblast numbers (density) in the alveolar walls.  
 
2. Innate immunity is in all likelihood also compromised due to the damage to cell-cell 
junctions in the alveolar walls which exposed the underlying basement membrane to 
foreign materials, such as oxidants that are inhaled, and may play a role in damage to the 
3D connective tissue framework. In addition the barrier function is compromised that 
will allow the penetration of the oxidants and other substances which may interfere with 
other cells such as the endothelial cells. The overall effect is a compromised innate 
immunity function. 
 
The effect of maternal nicotine on the lung structure and function is independent from normal 
growth and development of the offspring since BW was normal at birth and growth was 
proportional after birth and not different from that of the control animals. It therefore follows that 
the effect of maternal nicotine on lung integrity is due to an imbalance in the oxidant-antioxidant 
ratio induced by nicotine because when restoring the mothers’, fetus’ and neonate’s oxidant-
antioxidant ratio by supplementing the diet with tomato juice rich in lycopene, all the adverse 
effects on the developing lung was averted. 
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In conclusion, the data suggests that maternal (F0) nicotine exposure during gestation and lactation 
programmed the lungs of the F1 progeny to develop emphysematous lesions as a consequence of 
alveolar wall destruction and therefore diminished lung integrity. The data in the present study 
strongly suggests that the effects of grand maternal (F0) nicotine exposure may be inherited by the 
F2, F3, and possibly the F4 generation. Therefore, it is imperative to further explore the effects of 
grand maternal nicotine exposure on the lungs of the F2 and subsequent generations as well as the 
mechanisms involved in the transfer of premature aging of the lungs.  
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